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ABSTRACT 
Introduction: Melatonin is generated as a product of normal circadian rhythm and is also is 
thought to play an important role in maintaining bone mineral density (BMD) by reducing 
chronic inflammation. Postmenopausal women are at an elevated risk of BMD loss due to 
declining estrogen and a natural decrease in melatonin synthesis with increasing age. 
Endogenous melatonin production is largely influenced by exposure to external light cues, but 
recent research has indicated that serum melatonin may be increased by the consumption of 
melatonin-rich foods. The purpose of this study was to quantify dietary-derived melatonin and 
examine its effects on inflammation, BMD, and sleep in a sample of postmenopausal women.  
 
Methods: Cross-sectional analysis of data from the National Health and Nutrition Examination 
Survey (NHANES) was conducted to examine differences in melatonin consumption, BMD, and 
sleep in postmenopausal women with chronic and low-level inflammation indicated by level of 
C-reactive protein (CRP). Data from the years 2005-2010 was included in this study. 
 
Results: 110 postmenopausal women were included in the analysis with 55 subjects included in 
each inflammatory group. Individuals with normal CRP had a significantly greater intake of 
dietary melatonin (p=0.03) and higher BMD (p<0.05) than individuals with chronic 
inflammation. Normal inflammatory subjects also had a significantly higher intake of folate 
(p<0.0001), vitamin B6 (p=0.0005), and magnesium (p=0.0005) than subjects with chronic 
inflammation. Hours of sleep did not differ significantly with CRP level (p=1.0). Individuals 
with chronic inflammation exhibited a negative correlation between BMD and CRP (r= -0.27, 
p=0.04).  
 
Conclusions: The results suggest that dietary-derived melatonin may play an underlying role in 
mitigating inflammation and increasing BMD in postmenopausal women by reducing 
inflammation and oxidative stress. Melatonin may enhance the effects of other antioxidants and 
anti-inflammatory nutrients, and is part of dietary patterns rich in plant foods. Foods with 
melatonin also contain a variety of nutrients that act as coenzymes and cofactors for synthesis of 
endogenous melatonin. 
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Part I: Literature Review and Proposed Study Design 
Introduction 
Inflammation and Bone Mineral Density 
Chronic inflammation is thought to play a role in reducing bone mineral density (BMD) 
through a number of mechanisms. Pro-inflammatory cytokines, including c-reactive protein 
(CRP), tumor necrosis factor-alpha (TNF-!), interleukin (IL) 1, and immune cells are 
responsible for disrupting normal bone metabolism and preventing growth of new bone, or 
osteogenesis, from occurring.1,2,3 CRP is an acute phase reactant marker of chronic, low-grade 
inflammation. A better understanding of why blood CRP levels change may help clarify the way 
in which chronic inflammation alters BMD over time.2 The relationship between CRP and BMD 
has been previously evaluated using data obtained from the National Health and Nutrition 
Examination Survey (NHANES). This analysis found that CRP concentration was significantly 
associated with BMD in a dose-dependent relationship in both men and women.1 Specifically, 
there was an inverse correlation between CRP concentration and BMD in the lumbar spine 
independent of potential confounding variables.1 Forty-seven percent (47%) of the study 
participants were postmenopausal women. Within this subset of participants, those with high 
CRP levels were also more likely to have a low BMD, osteopenia, or osteoporosis in the femur.1 
High CRP has also been shown to be a good predictor of fractures in individuals with 
osteoporosis.2   
To understand the link between CRP and BMD, it is necessary to consider several cell 
signaling pathways commonly upregulated by inflammation. The receptor activator of nuclear 
factor-"# is the protein RANKL, a pro-inflammatory cytokine that binds to the RANK receptor 
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of osteoclasts to promote resorption, which is the breakdown of bone.2 Osteoprotegerin (OPG) is 
an antagonist to RANKL that prevents RANKL from binding to the RANK receptor, therefore 
preventing bone breakdown.2 The ratio of RANKL/OPG is increased by a number of factors, 
including low estrogen and glucocorticoids, and plays a role in regulating T cells and B cells and 
the production of inflammatory cytokines.2 In addition, TNF-! has been shown to directly 
increase the amount of RANKL, allowing osteoclast precursors to become mature osteoclasts.2 
Therefore, bone formation and resorption may be related to CRP concentration, as CRP is 
produced by the liver in response to TNF-!, IL-1, and IL-6 secretion.2  
TNF-! is also known to promote the production of osteoclasts, while inhibiting the 
development of mesenchymal stem cells (MSC) to osteoblasts, thereby increasing bone 
resorption.3 TNF-! may exert its effects on BMD by way of the bone morphogenetic protein 
(BMP) pathway, which is responsible for regulating osteoblasts and osteoclasts.3 BMP promotes 
osteogenesis by binding to and activating the BMP receptors of bone, resulting in the 
phosphorylation of receptor-regulated R-SMAD proteins.3 R-SMADs then form complexes with 
other SMAD proteins, which act as transcription factors to up regulate genes involved in 
osteogenic differentiation and production of new bone.3 However, SMAD ubiquitination 
regulatory factor 1 (SMURF1) causes the degradation of SMAD proteins, which turns off SMAD 
signaling and osteogenesis.3 In vitro studies have shown that TNF-! not only up regulates 
SMURF1 but also inhibits osteoblasts.3 Furthermore, TNF transgenic mice had SMAD protein 
levels and BMDs that were significantly lower than levels found in wild-type mice.3 This 
demonstrates an important link between the inflammatory response of the immune system and 
bone formation, and that chronic inflammation may play a role in reducing BMD in 
postmenopausal women.  
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In summary, chronic inflammation from pro-inflammatory cytokines and acute phase 
proteins, including CRP, TNF-!, and IL-1, stimulates the cell signaling molecules RANKL and 
SMURF1 that in turn stimulate bone resorption. Other signaling molecules, including OPG and 
BMP, antagonize the effects of RANKL and SMURF1, which promote growth of new bone and 
prevent bone loss. Therefore, it is important to prevent excessive production of pro-inflammatory 
molecules to maintain the integrity of bone health.  
 
Melatonin’s Influence on BMD and Inflammation  
Melatonin is a hormone that is important for maintaining adequate BMD. Endogenous 
melatonin is synthesized in the pineal gland when light is transferred through the 
suprachiasmatic nuclei, retinohypothalamic tract, and the sympathetic nervous system.4 At the 
molecular level, melatonin is formed when tryptophan is hydroxylated by tryptophan 
hydroxylase (TPH) to form 5-hydroxytryptophan (5-HTP), which is then decarboxylated by 
aromatic amino acid decarboxylase (AADC) to form 5-hydroxytryptamine (5-HT/serotonin) 
(Figure 1).5,6 Serotonin is then converted to N-acetylserotonin using arylalkylamine-N-
acetyltransferase (AANAT), which is converted to melatonin with hydroxyindole-O-
methyltransferase (HIOMT) (Figure 1).5 Light inhibits the synthesis of melatonin whereas 
darkness activates melatonin production, which is why melatonin promotes sleep at night.4,7 
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Figure 1. Pathway of melatonin synthesis, nutrient influences on pathway enzymes, and 
proposed actions of melatonin in the body. Adapted from Peuhkuri K, Sihvola N, Korpela R. 
Dietary factors and fluctuating levels of melatonin. Food & Nutrition Research. 2012;56. 
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When melatonin is released into circulation in the blood, a portion will be metabolized in the 
liver by cytochrome P450, where it is converted to 6-sulfatoxymelatonin (6-SMT/aMT6S) to be 
excreted in urine (Figure 2).8 However, approximately 30% of circulating endogenous melatonin 
bypasses metabolism in the liver and is taken up by other tissues.8 In all types of cells, melatonin 
may be non-enzymatically metabolized to 3-hydroxymelatonin, which is used to scavenge free 
radicals. Alternatively, melatonin may be converted to kynuramine derivatives that function as 
anti-inflammatory molecules and antioxidants (Figure 2).8 Important kynuramine derivatives 
include N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-
methoxykynuramine (AMK) (Figure 2).8 Synthesis of AFMK and AMK is thought to occur in 
extrahepatic tissues because these tissues have reduced cytochrome P450 activity, which 
prevents melatonin from being converted to 6-SMT/aMT6S.8  
! 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Metabolism of melatonin in the liver and extrahepatic tissues. Adapted from Pandi-
Perumal S, Srinivasan V, Maestroni G, Cardinali D, Poeggeler B, Hardeland R. Melatonin. FEBS 
Journal. 2006;273(13):2813-2838. 
 
Melatonin may promote increased BMD in a number of ways. While melatonin is primarily 
synthesized in the pineal gland, there is evidence that bone marrow may also make melatonin.  
The membrane-bound melatonin G protein-coupled receptors known as MT1 and MT2 are 
present in both osteoclasts and osteoblasts.4,9 It is thus possible that bone cells take up circulating 
melatonin or generate melatonin locally and convert it to 3-hydroxymelatonin, AFMK, and 
AMK to maintain bone integrity. In vitro studies have demonstrated that rat bone cells exposed 
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to melatonin had elevated uptake of calcium, cell differentiation of pre-osteoblasts, and increased 
expression of bone marker proteins, including matrix sialoprotein, osteopontin, osteocalcin, and 
alkaline phosphatase.8  
Melatonin is also known to increase BMD by preventing oxidative stress in bone cells.4,8 
Studies with melatonin in vitro and in vivo have demonstrated that melatonin is superior to 
glutathione at scavenging hydroxyl radicals, and more effective at neutralizing peroxyl radicals 
than vitamin E, C, and #-carotene.10,11 Research has shown that melatonin has the ability to 
scavenge peroxynitrite anions and hydrogen peroxide, as well as limiting the production of 
superoxide radicals at the electron transport chain.12 Specifically, melatonin may prevent leakage 
of electrons at the electron transport chain and increase transfer of single electrons between 
components of the chain.8 Melatonin may also be converted to a melatonyl cation radical at 
cytochrome c, which allows melatonin to act as a final electron acceptor to reduce excess O2- 
production that could lead to bone damage.8 Melatonin is also known to increase $-
glutamylcysteine synthetase, resulting in elevated glutathione production and increased 
expression of superoxide dismutase, both of which are endogenous antioxidants that scavenge 
reactive oxygen species (ROS).11 Oxidative stress increases the production of RANKL, thereby 
allowing osteoclasts to differentiate and result in bone resorption.4 Melatonin combats bone 
resorption caused by oxidative stress by acting as an antioxidant to scavenge ROS.4,8 Further, 
one molecule of AFMK, which is a product of melatonin metabolism in extrahepatic tissues, has 
the ability to scavenge four free radicals, which may also protect BMD and prevent bone 
resorption.8 It has also been suggested that melatonin has the ability to promote osteogenesis and 
increase BMD by inhibiting peroxisome proliferator-activated receptor gamma (PPAR-$).4 By 
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inhibiting PPAR-$, MSCs would be directed to mature into osteoblasts instead of osteoclasts and 
bone marrow adipogenesis would be reduced, therefore increasing BMD.4  
Melatonin is also responsible for regulating the immune system and lymphoid tissue 
differentiation by reducing the inflammatory state.6,7 As previously discussed, pro-inflammatory 
cytokines reduce BMD via activation of osteoclasts and inhibition of osteoblasts. Melatonin has 
the ability to inhibit nuclear factor-"#, TNF-!, and RANKL and prevent these inflammatory 
cytokines from disrupting osteogenesis.8,7 Within mouse osteoblasts, melatonin was able to 
reduce RANKL mRNA in a dose-dependent manner and increase the expression of OPG mRNA 
by up to 550%.4 Other studies have demonstrated that melatonin can prevent osteoclast 
differentiation by reducing the expression of TNF-! and IL-1 mRNA.9 TNF-! is involved in the 
upregulation of SMURF1, which inhibits osteoblast activity, but melatonin’s ability to inhibit the 
production of TNF-! mRNA and its subsequent actions on SMURF1 activation and SMAD 
protein degradation enables MSC to promote bone formation.3 Melatonin is also responsible for 
reducing nuclear factor-"# activation and preventing the subsequent activation of osteoclasts and 
bone resorption.8 Since the secretion of melatonin and its impact on the immune system are 
closely linked, it is clear that both factors play a combined role in determining bone metabolism.   
Overall, there is evidence that melatonin is intimately tied to BMD, as bone cells contain 
melatonin receptors and may have the ability to synthesize melatonin locally. Oxidative stress 
negatively affects osteogenesis, but melatonin acts as a potent antioxidant by directly scavenging 
free radicals and increasing the production of other endogenous antioxidants. Melatonin also 
inhibits the production of pro-inflammatory cytokines and prevents these molecules from 
activating osteoclasts. Therefore, melatonin may be an important molecule to stop bone loss and 
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increase the formation of new bone in individuals with elevated inflammation and oxidative 
stress.  
 
The Effects of Circadian Rhythm, Disruption of Melatonin Synthesis, and Inflammation on BMD 
Darkness is one of the main signals that stimulates the production of melatonin and allows 
for quality sleep and regulation of circadian rhythm.4,7 Therefore, one must be exposed to enough 
darkness at night and experience a normal circadian rhythm in order for adequate endogenous 
melatonin production to occur. However, individuals with sleep disorders, those who are awake 
during the normal sleep period, and individuals exposed to excessive light before sleep 
experience circadian disruption that may compromise melatonin metabolism.7 Circadian rhythm 
dysfunction and subsequent inhibition of melatonin production may cause problems with 
transcriptional feedback loops, which cause cell permeability to increase, the immune system to 
over activate, and pro-inflammatory cytokine production to increase.7 With the presence of an 
inflammatory state and a reduction in serum melatonin, it is possible that BMD may be 
negatively affected by circadian rhythm disruption. In fact, studies have shown that night 
workers exhibit both lower than normal levels of melatonin and a greater risk of fractures from 
osteoporosis, suggesting that the inhibition of melatonin plays a role in BMD.4 This is significant 
in that approximately 70 million individuals meet the criteria for a sleep disorder.7   
Melatonin production may also be inhibited when inflammatory cytokines, including TNF-!, 
IL-1#, and IL-6, prevent the pineal gland from properly metabolizing melatonin.6 Since the 
pineal gland is not protected by the blood brain barrier, pro-inflammatory cytokines are able to 
alter its function by reducing melatonin production and increasing synthesis of inflammatory 
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cytokines.6 There are a number of physiological mechanisms by which pro-inflammatory 
cytokines may prevent the pineal gland from synthesizing adequate melatonin. IL-1# injections 
in the intracerebroventricular region of ewes were shown to reduce the expression of TPH at the 
gene level, as well as decrease the amount of 5-HTP in the pineal gland.6 That study also found 
that the concentration of AANAT and its gene expression was decreased with the addition of IL-
1#.6 This suggests that IL-1# may reduce pineal gland production of melatonin primarily through 
reduced gene expression of TPH and AANAT.6    
Additional studies have shown that elevated TNF-! significantly reduces the amount of 
melatonin produced at night in women experiencing acute inflammation.6 When TNF-! levels 
dropped to a normal level, nighttime melatonin production was restored, which demonstrates that 
pro-inflammatory cytokines have the ability to disrupt melatonin metabolism.6 When considering 
the important role that melatonin plays in promoting proper BMD, it is reasonable to suggest that 
inflammatory-mediated inhibition of melatonin production could negatively impact osteogenesis. 
Additional studies are needed in this area to adequately evaluate the effects of chronic 
inflammation on melatonin synthesis and the implications for bone metabolism.  
 
Food as a Source of Melatonin 
A large number of foods contain melatonin. The ability of humans to obtain melatonin from 
exogenous sources raises the question of whether dietary melatonin could influence important 
body functions, including bone metabolism and inflammatory pathways.5,13,14 Plants are known 
to contain significantly higher levels of melatonin than animals. Melatonin has been found in 
many plant parts, including leaves, flowers, seeds, roots, and bulbs.14 Plant melatonin 
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concentration varies depending on environmental conditions, genotype, and stage of 
development.13,14,15  Melatonin is thought to act as a defense mechanism for plants to enable 
them to survive harsh conditions, since they cannot physically move to avoid exposure.13 Since 
animals are mobile and can avoid these conditions, they may have less of a need to produce high 
levels of endogenous melatonin.13 For example, genes that up regulate melatonin production 
were found to be elevated in plants under heat stress and increased melatonin concentrations 
were present in plants exposed to high UV radiation.14 Plant foods with notable levels of 
melatonin include pistachios, walnuts, tart cherries, grapes, corn, rice, barley, and herbs, such as 
St. John’s wort (Table 1).5,13-30 In addition, significant levels of melatonin have been found in 
milk, coffee, beer, wine, and other products that are fermented with yeast.5,23,17 Since a wide 
variety of plant-based foods contain melatonin concentrations that may be clinically relevant, it 
can be hypothesized that ingesting these foods might increase serum melatonin and contribute to 
health benefits, such as increased BMD and a reduced inflammatory response. 
Recent studies have also demonstrated that other animal products, including eggs, salmon, 
and meats contain moderate amounts of melatonin (Table 1).24 Since animal products constitute a 
large part of the diet of industrialized countries, it is important to analyze the potential 
contribution of these foods to blood melatonin concentration.24 It has been suggested that 
melatonin might be produced in other tissues besides the pineal gland, such as the skin and the 
gut.24 Extrapineal melatonin may be used as an antioxidant and to reduce inflammation locally, 
rather than being released systemically to contribute to overall blood melatonin concentration; 
this is why melatonin could be present in animal tissues typically consumed by humans.24 Of the 
available research, eggs seem to contain the highest concentration of melatonin and the levels in 
meats compare to those found in some varieties of seeds.24,14 Cow’s and goat’s milk have also 
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been identified as having low concentrations of melatonin.25 Although melatonin in meats and 
fish may help preserve shelf life and flavor by acting as an antioxidant to prevent oxidation, it is 
possible that the finite amount of melatonin in a piece of meat would eventually be degraded to 
combat oxidation.24 Therefore, the age of an animal product, as well as how an animal was raised 
and what it was fed, would make it difficult to define the exact melatonin content of an animal 
product. Based on currently available research, it is unclear whether meats and other animal 
products make significant contributions to blood melatonin concentration.   
 
Table 1. Examples of plant and animal foods containing melatonin. Melatonin concentrations 
were averaged if multiple values were reported in the literature.5,13-30 
Name of Food Melatonin Concentration (ng/g) 
Vegetables  
Asparagus 0.01 
Beet 0.01 
Black olive 0.31 
Cabbage 0.2 
Carrot 0.28 
Cauliflower 0.82 
Celery 7 
Chilies (dried) 1.35 
Corn 378.31 
Cucumber 0.44 
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Garlic 0.58 
Ginger 1.01 
Hunag-qin root 7110 
Kohlrabi 7.8 
Lupin root 55.6 
Onion 0.16 
Radish 0.68 
Rutabaga 5.6 
Taro 0.05 
Tomato 0.48 
Tomatoes (dried) 128.75 
Turnip 0.6 
  
Fruits  
Apple 0.11 
Banana 0.29 
Grapes (flesh) 0.005 
Grapes (skin) 62 
Kiwi 0.02 
Mango 0.7 
Mango juice 0.7 
Orange 0.15 
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Orange juice  0.15 
Papaya 0.24 
Papaya juice 0.241 
Pineapple 0.21 
Pineapple juice 0.30 
Pomegranate 0.17 
Strawberry 5.17 
Sweet cherry 20.09 
Tart cherry 13.95 
  
Animal Foods  
Beef (raw) 2.1 
Chicken (meat and skin, raw) 2.3 
Cow’s milk 0.014 
Dried egg solids 6.1 
Lamb (raw) 1.6 
Pork (raw) 2.5 
Salmon (raw) 3.7 
Yogurt 0.13 
  
Grains (cooked)  
Barley 15.11 
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Bread (Yeast-leavened) 1.17 
Oat 13.92 
Rice 31.09 
Rye 0.05 
Wheat 25.01 
  
Seeds  
Black mustard 129 
Coriander seed 7 
Flax seed 12 
Green cardamom 15 
Sunflower seed  29 
White mustard 189 
  
Nuts and Oils  
Almonds 39 
Olive oil 0.079 
Pistachios 230,000 
Walnut 1.21 
  
Sprouts  
Alfalfa sprouts 0.65 
Broccoli sprouts 0.44 
! 16 
Lentil sprouts 0.22 
Mung bean sprouts 0.17 
Onion sprouts 0.30 
Radish sprouts 0.54 
Red cabbage sprouts 0.86 
Sunflower sprout 0.77 
  
Herbs  
Feverfew, gold 1920 
Feverfew, green 2450 
Morning glory leaves 0.0005 
Morning glory shoots 0.004 
Red pigwid (shoots) 0.2 
St. John’s wort flowers 4390 
St. John’s wort leaves 1750 
 
Recent studies have attempted to evaluate the effects of melatonin-rich foods on melatonin 
concentrations in humans, primarily by measuring plasma melatonin levels.5 Humans produce 
between 10-80 µg of melatonin during the night, which subsequently declines during the day.5 
Studies in healthy females have illustrated that plasma melatonin ranges from 19.0-197 pg/mL in 
full darkness at 3:00 AM, and that levels significantly decrease upon exposure to light at 8:00 
AM to a range of 3.3-93.2 pg/mL.31 A different research laboratory considers normal serum 
melatonin ranges during the day and night to be 2.0-80 pg/mL and 18.5 -180 pg/mL 
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respectively.32 Current lab reference ranges for salivary melatonin, which is 40% of that found in 
plasma, are less than 10.5 pg/ml from 7am-9am, less than 0.88 pg/ml from 3pm-5pm, and 2.53-
30.67 pg/ml from 2:30am-3:30am.33,5 Observations in mammals show that tissue and blood 
levels of melatonin consistently stay within specific ranges during the daytime and increase to set 
ranges at night.13 It is also important to measure the deactivated metabolite of melatonin, 6-
SMT/aMT6S, which is excreted in the urine and is an accurate indicator of the concentration of 
melatonin in the blood, as melatonin is quickly put into circulation and metabolized.5 
There is promising research that suggests a healthful diet containing melatonin-rich plant 
foods might have a positive effect on plasma melatonin concentration. Given the important role 
of melatonin in the body, it is plausible that melatonin consumption could reduce inflammation 
and increase BMD. Evidence also suggests that melatonin from food has the ability to increase 
serum antioxidant capacity and reduce oxidative stress, which could improve BMD.12 
Consumption of walnuts by rats was shown to significantly increase serum melatonin levels in 
comparison to rats that did not receive walnuts.28 A study examining vegetable intake in women 
found a 16% higher excretion of 6-SMT/aMT6S for women consuming an amount of vegetables 
in the highest quartile compared to participants in the lowest quartile.34 A similar study found 
that study participants consuming an average of 1288 ng of melatonin per day from vegetables 
significantly increased 6-SMT/aMT6S excretion, illustrating that plasma melatonin 
concentration and breakdown of melatonin likely increased.35 Additional studies have shown that 
consumption of juice from oranges, pineapples, and bananas increased serum melatonin 
concentration and melatonin metabolism, as measured by 6-SMT/aMT6S, and elevated serum 
antioxidant capacity, as measured by increased single electron and hydrogen atom transfer at the 
electron transport chain.36,29  
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It is, however, unknown whether melatonin in food directly influences plasma concentration 
or whether other compounds in food, such as vitamins, minerals, and tryptophan, increase 
melatonin production in the pineal gland.5 It is currently known that consuming an adequate 
amount of dietary tryptophan promotes the synthesis of melatonin, as tryptophan is the starting 
molecule for endogenous melatonin production.5 Indeed, tryptophan restriction has been shown 
to reduce melatonin production.5 Consumption of tryptophan-rich foods has the ability to 
improve sleep time and quality, as well as increase excretion of 6-SMT/aMT6S.37 Other vitamins 
and minerals may also increase endogenous melatonin production. For example, it is known that 
folate and vitamin B6 are used as coenzymes for TPH and AADC to convert tryptophan to 
serotonin.5 AANAT converts serotonin to N-acetylserotonin and may require zinc and 
magnesium to function properly.5 In addition, it has been suggested that n-3 polyunsaturated 
fatty acids (PUFA) are needed for melatonin synthesis, as rats consuming a diet deficient in n-3 
PUFA had inadequate secretion of melatonin at night and possible disruption of AANAT.5 While 
some studies have shown positive effects of nutrients in food on plasma melatonin concentration 
and secretion of 6-SMT/aMT6S, other studies have found no association between the 
aforementioned nutrients and melatonin status.5 Furthermore, individuals with a limited caloric 
intake may have reduced melatonin synthesis since the pineal gland requires glucose to 
synthesize melatonin.5 Studies have shown that individuals consuming less than 300 kcal per day 
for a period of 2-7 days had a 20% decrease in blood melatonin concentration.5 
The research presented here is designed to further explore the links between dietary sources 
of melatonin and inflammation and bone mineral density. Recent analysis shows that commonly 
eaten foods contain significant levels of melatonin that may directly contribute to plasma 
melatonin concentration and metabolism of melatonin to 6-SMT/aMT6S. Given the important 
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role of melatonin as an antioxidant and regulator of sleep and inflammation, melatonin may be 
an under-recognized nutrient that positively contributes to osteogenesis and increased BMD.  
 
Study Population: Postmenopausal Women 
This research project will focus on postmenopausal women. Women are at a higher risk of 
bone loss, osteoporosis, and fractures after menopause due to declining estrogen levels, which 
reduces the ability of calcium to be incorporated into bone.38 Of the 45 million adults in America 
over age 50 who have osteopenia and osteoporosis, 80% of these individuals are women.39 
Current recommendations for preventing bone loss include consumption of adequate calcium and 
vitamin D, engaging in weight-bearing exercise, monitoring bone health, and receiving 
medication to prevent further bone loss.39 However, it is known that inflammatory markers, 
including CRP, are elevated in women with osteoporosis and that there is a shift to higher serum 
CRP, TNF-!, IL-1!, and IL-6 in postmenopausal women.40,41,42 Additional studies have 
demonstrated that there is a link between CRP concentration and fracture risk from osteoporosis, 
and that it is important to develop a greater understanding of the mechanism between the 
immune system and bone metabolism.2 Identifying additional dietary and lifestyle factors that 
affect systemic inflammation may be a key consideration in better understanding the 
pathogenesis of osteoporosis in women. Research exploring the relationship between these 
factors in postmenopausal women is currently scarce.2  
While it is understood that melatonin confers anti-inflammatory benefits and promotes 
proper bone metabolism, it is not completely clear how the age-related decline of melatonin 
secretion could affect these systems in postmenopausal women.9,4 Since melatonin secretion 
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naturally declines with age, it has been suggested that this may contribute to the manifestation of 
sleep disorders, as well as problems with other body systems that require melatonin to properly 
function.43 Reduced melatonin production is known to affect the normal 12 hour light/12 hour 
dark cycle of the circadian rhythm, which disrupts sleep.8 Studies have found that 
postmenopausal women with sleep disorders had significantly lower production of melatonin at 
night than women without sleep problems.43 Thus, there is reason to suspect that abnormal sleep 
patterns may reduce melatonin release, subsequently increasing chronic low grade inflammation 
and oxidative stress, and reducing BMD. 
Supplemental melatonin has the ability to increase BMD in postmenopausal women by 
potentially reducing the inhibition of osteoblasts by oxidative stress.44 Specifically, low-dose 
melatonin supplements provided to postmenopausal women at 1 mg/day for one year was able to 
significantly increase femoral neck BMD compared to controls and a dose of 3 mg/day 
significantly increased spine BMD.44 Further, providing a dose of melatonin from 0.5-6.0 
mg/day to individuals with an age-related decline in melatonin synthesis may promote a normal 
sleep/wake cycle.8 Most drugs that are currently used in individuals with osteoporosis are 
expensive and may have detrimental side effects, but melatonin has been shown to be both 
effective and safe at promoting osteogenesis and preventing bone loss.9,44 
There is limited knowledge on whether melatonin from food can provide similar anti-
inflammatory benefits and promote osteogenesis in humans. Exploring how a diet containing 
melatonin-rich foods affects inflammation, circadian rhythm, and BMD would provide a better 
understanding of how dietary-derived melatonin, as well as nutrients that enhance endogenous 
melatonin production, could improve BMD in postmenopausal women. Current dietary 
recommendations for preventing bone loss in this life stage focus on adequate calcium and 
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vitamin D intake, but it is possible that endogenous and exogenous sources of melatonin may 
play an equally important role in promoting bone health.39 Knowing whether there are additional 
therapeutic foods that could be recommended to postmenopausal women to prevent 
inflammation, increase serum melatonin, and prevent loss of BMD could be an additional 
strategy to mitigate osteopenia and osteoporosis. Therefore, researching the individual and 
combined effects of inflammation, sleep, and dietary-derived melatonin on BMD in 
postmenopausal women would provide valuable insight into this relatively unexplored field and 
in a population at a higher risk for bone loss.  
 
Interactions Between Estrogen and Melatonin and Effects of Age on Melatonin Synthesis 
Melatonin production naturally decreases with age and therefore may play a role in the 
reduced bone health that many older adults experience.9 This holds true for menopausal women 
and thus may be important in the manifestation of osteoporosis.4 Studies examining the effects of 
melatonin on osteoblasts both in vitro and in vivo with rats have shown that, along with 
decreased secretion of melatonin, MT1 receptors for melatonin on osteoblasts also reduce in 
number with age.9,4 Since MT1 receptors of bone are thought to allow melatonin to exert 
beneficial effects on BMD, it is suggested that an age-related decline in MT1 may cause 
osteoblasts to lose their sensitivity for the limited amount of melatonin available.4  
Further, melatonin may interact with estrogen to produce beneficial effects on BMD. Studies 
in rats have demonstrated that estrogen and melatonin work in a synergistic relationship to 
improve bone health.4 In ovariectomized animals receiving 25 µg/ml of melatonin per day, bone 
alkaline phosphatase levels were elevated compared to control animals, and their BMD and bone 
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mineral content (BMC) declined significantly after 60 days without estrogen.4 However, the 
ovariectomized animals that did not receive a melatonin supplement had significantly increased 
levels of urinary deoxypyridinoline, which is a marker for bone resorption.4 In a similar study, it 
was found that ovariectomized rats receiving both melatonin and estrogen had higher BMD of 
the tibia and whole skeleton than rats receiving melatonin alone.4 While these studies were 
performed in animal models, it is plausible that reduced estrogen availability during 
postmenopause may decrease the effectiveness of dietary and supplemental melatonin to increase 
BMD.4 Therefore, a combination of declining estrogen that occurs during and after menopause, 
as well as the age-related reduction in melatonin secretion, may negatively affect BMD, leading 
to osteopenia and osteoporosis. However, providing postmenopausal women with adequate 
melatonin from food and supplements and ensuring that estrogen levels are adequate may help 
prevent age related loss of BMD.8  
 
Study Objectives 
This study was conducted to evaluate the relationship between dietary melatonin, CRP, sleep, 
and BMD in postmenopausal women. The effect of nutrients on CRP, BMD, and melatonin 
intake were evaluated, including calories, protein, vitamin B6, vitamin B12, folate, vitamin C, 
magnesium, and zinc.  
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Methods 
Study Design 
We conducted a cross-sectional study consisting of a secondary data analysis of diet and 
biomarkers of inflammation in postmenopausal women. We used data from the National Health 
and Nutrition Examination Survey (NHANES) collected between 2005-2010. The NHANES 
survey contains data on a sample of participants who are representative of the general population 
of the United States.45 NHANES conducts physiological and laboratory tests, as well as dietary 
and health surveys, to assess nutrition status, disease risk, and disease prevalence in study 
participants.45 The NHANES variables of interest for this study included blood CRP 
concentration, femur BMD, sleep patterns, two-day diet records, total nutrient intake, physical 
activity, blood HDL cholesterol level, and standard biochemistry profile.  
We used CRP as a measure of inflammation, as it is a sensitive, nonspecific indicator of 
chronic inflammation and was successfully used for development of the Dietary Inflammatory 
Index (DII).46,47 CRP is released within 6-10 hours following an inflammatory event, and has a 
short half life of 5-7 hours, which means that the influence of diet and lifestyle on serum CRP 
concentration can be observed quickly.47 CRP is an important inflammatory marker for this 
study, as elevated levels are associated with reduced BMD, and because melatonin has the ability 
to reduce serum CRP by acting as an anti-inflammatory molecule.1,2,48 Medical nutrition therapy 
guidelines define a low inflammatory-risk serum CRP concentration as below 1.0 mg/L, a 
moderate risk from 1.0-2.9 mg/L, and a high risk as more than 3.0 mg/L.47 Concentrations equal 
to or greater than 10.0 mg/L are likely due to an acute inflammatory response, rather than 
chronic inflammation.47  
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Female participants were included in our study if their last menstrual period occurred more 
than 12 months before the time of data collection due to menopause. Subjects were included if 
they had data collected for our variables of interest, including a DXA scan of the femur, 2 days 
of 24-hour dietary recalls, CRP data, HDL cholesterol measurement, standard biochemistry 
profile, sleep data/sleep disorder information, and physical activity data. Subjects were also 
included if they had a CRP of < 10.0 mg/dL. Participants were excluded if they had not gone 
through menopause, if they did not have data for our primary variables of interest, including 
femur BMD, 24-hour dietary recalls, and sleep disorders information, and if they had a CRP of > 
9.9 mg/dL. Once study participants were selected, they were separated into two groups according 
to their level of inflammation with a CRP level of 2.0 – 9.9 mg/dL indicating chronic 
inflammation and a CRP of less than 2.0 mg/dL indicating low/normal inflammation. We 
evaluated serum HDL cholesterol, as this is an additional indicator of chronic inflammation that 
may be used to validate CRP concentration.47 Alkaline phosphatase was also included in our 
analysis, as multiple studies have shown that it is a marker for bone turnover and bone loss, 
which could be used to assess degree of inflammation in our study sample.49,50,51  
Our data included information about ethnicity, education level, age, socioeconomic status, 
smoking, alcohol, and medications. Although these variables provide an opportunity to 
statistically control for these factors in analysis, we were unable to include them in our analysis. 
The large number of variables of interest and the limited number of participants that met the 
inclusion criteria made it necessary to limit the number of environmental and socioeconomic 
covariates controlled for in the statistical models. We therefore limited our analysis to relevant 
dietary components and major biomarkers of inflammation. Increasing the number of covariates 
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would have increased the dimensionality of the dataset to a degree that would have reduced our 
ability to assess the relationships between these variables and dietary melatonin.  
 
Data Collection 
DXA Scan: BMD was collected from study participants using a DXA scan of the femur.45 The 
Hologic QDR 4500A fan beam X-ray body densitometer was used to evaluate participant BMD 
and BMC.45  
CRP Concentration: Latex-enhanced nephelometry and a Behring Nephelometer were performed 
to assess participant CRP levels.45 
Sleep Disorders: A Computer-Assisted Personal Interviewing system was used to administer a 
questionnaire to study participants to evaluate sleeping habits.45 
Physical Activity: A Computer-Assisted Personal Interviewing system was administered to 
collect information on participant physical activities and sedentary activities.  
Diet and Supplements: Two, 24-hour dietary recalls were performed by trained interviewers to 
assess participant food and nutrient intake. The first interview was conducted in person at the 
NHANES Mobile Examination Center and a variety of measuring and reference tools were used 
to help participants estimate food portion sizes.45 The second interview was conducted via 
telephone 3-10 days after the first recall, and participants were provided with measuring tools 
and portion guides to estimate amounts of food consumed.45  
Standard Biochemistry Profile: The NHANES Laboratory/Medical Technologists Procedures 
Manual (LPM) was used to collect and process participant samples using the Beckman Synchron 
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LX20.45 Each sample was frozen and sent to the National Center for Environmental Health for 
analysis.45 Alkaline phosphatase was measured using a 2-amino-2-methyl-1-propanol buffer.45  
HDL Cholesterol: The LPM was used to collect and process blood samples and an HDL 
cholesterol direct immunoassay method was used to quantify HDL.45  
 
Assessment of Dietary Melatonin 
We quantified food melatonin content using the melatonin concentration (ng/g) of individual 
foods that have been reported in the literature. If multiple melatonin concentrations were 
reported for a particular food, the values were averaged to derive an approximate melatonin 
concentration. The individual food serving sizes collected by NHANES in the two, 24-hour 
dietary recalls were reported in grams, which allowed us to quantify an approximate number of 
nanograms of melatonin consumed for each serving of food.  
We included the melatonin concentrations of raw, unprocessed fruits, vegetables, and juices, 
but excluded produce that had been cooked or processed, as studies have shown that melatonin is 
degraded at high temperatures.23  Additional literature reports that heat processing and chemical 
treatment of olive oils may alter melatonin concentration.17 Based on this observation, it is 
plausible that other foods exposed to excessive processing or heat would also have a limited 
melatonin content. Meats and eggs were excluded from our analysis, as there is insufficient 
evidence available to show the degree to which melatonin is degraded in animal products after 
cooking. Yeast-leavened breads were included, as evidence shows that fermentation enables a 
significant amount of melatonin to remain intact in the crumb of bread after baking.23 Cooked 
and processed foods containing wheat, barley, rye, oats, and rice were included if specified as 
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whole grain, as available literature has reported that these grains contain melatonin after 
exposure to hydrothermal processing of 200°C.30 Combination foods containing multiple 
ingredients were excluded since we could not determine the number of grams of each individual 
ingredient. We also included herbs and supplements, such as St. John’s wort, that would 
significantly contribute to total melatonin intake. While we originally intended to include 
melatonin supplements in participants’ dietary melatonin consumption, the single individual who 
reported taking a pure melatonin supplement was identified as an outlier when conducting our 
tests for normality. Since melatonin supplements contribute a significantly greater amount of 
melatonin than that obtained from whole foods, we decided to exclude the single individual 
taking a melatonin supplement from our analysis. Therefore, we only considered melatonin 
derived from foods in our analysis. 
In addition, while both coffee and wine contain high concentrations of melatonin, caffeine 
and ethanol may interfere with melatonin metabolism.5 Caffeine blocks adenosine receptors that 
enable AANAT production, which inhibits endogenous melatonin synthesis.5 Caffeine also 
prevents melatonin breakdown by competing with melatonin for binding with the cytochrome 
P450 detoxification enzyme in the liver, which results in elevated blood melatonin levels.5 
Studies have obtained mixed results on alcoholic beverages containing melatonin and have 
shown that ethanol reduces 6-SMT/aMT6S output by 9% after two drinks while some have 
shown that alcohol elevates serum melatonin.5 However, it is suggested that ethanol disturbs 
AANAT gene expression and may impair normal sleep patterns.5 Therefore, we excluded coffee, 
beverages containing similar amounts of caffeine, and alcoholic beverages from the dietary 
melatonin score.  
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We assume that exogenous preformed melatonin would bypass the pathway where melatonin 
is synthesized from tryptophan, and have the ability to directly enter systemic circulation or enter 
tissues where needed (Figure 1). While we acknowledge that a proportion of dietary tryptophan 
is used for endogenous melatonin synthesis, dietary averages and serum concentrations of 
tryptophan were not available for our population of interest, thus preventing us from including 
tryptophan in the dietary melatonin score.  
 
Statistical Analysis 
Our analysis was conducted in SAS statistical software (SAS 9.4, English, Cary, NC) and 
SPSS statistical software (IBM SPSS Statistics 24, Armonk, NY). Prior to conducting all 
analyses, we checked for the normality of all variables and made logarithmic and inverse 
transformations as necessary. The combined dataset with the two groups of study participants 
with chronic inflammation (CRP 2.0-9.9 mg/dL) and low inflammation (CRP < 2.0 mg/dL) 
contained a large number of variables that required us to reduce the dimensionality of the dataset. 
We used factor analysis to reduce the number of variables included in our analysis, and to 
identify the most relevant variables contributing to differences observed between the two groups. 
In addition, we used a discriminant function analysis to create a further refined predictive model 
to assess which predictor variables provided the maximum separation between the chronic and 
low inflammatory groups. After conducting factor analysis and discriminant function analysis 
and identifying the dietary, biochemical, BMD, and lifestyle factors explaining the majority of 
the variance between the chronic inflammatory and normal inflammatory groups, we focused on 
examining the relationships between these variables and CRP level for the remainder of our 
analysis.  
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Means tests were used to compare variables of interest between the chronic inflammatory 
and low inflammatory groups. Simple linear regression was used to examine the relationship 
between variables of interest and CRP level between each group. We also conducted multiple 
regression analysis within each inflammatory group to identify possible interactions between 
dietary, biochemical, BMD, and lifestyle variables. As a supplement to the linear regression, a 
path analysis of significant and borderline significant relationships between variables was 
performed within each inflammatory group, which enabled us to graphically represent variable 
relationships. Finally, we evaluated dietary sources of melatonin within the chronic and normal 
inflammatory groups to quantify the percent contribution of each food group to total melatonin 
intake. These food groups included fruits, vegetables, grains, dairy, and nuts and seeds.  
 
 
 
 
 
 
 
 
 
 
! 30 
Part II: Thesis Manuscript 
Introduction 
Melatonin plays an important role in a number of biological processes, including regulation 
of inflammation and oxidative stress, promoting BMD, and regulating circadian rhythm. It has 
been suggested that melatonin produced endogenously in the pineal gland, as well as dietary-
derived melatonin, are converted to metabolites that are taken up by extrapineal tissues to reduce 
inflammation and scavenge free radicals.8 Melatonin may also be taken up by bone via melatonin 
receptors and bone may have the ability to produce melatonin locally, as in vitro studies suggest 
that melatonin increases the activity of osteoblasts and bone growth.4,8,9  
Inflammation and oxidative stress lead to degradation of bone, through activation of 
RANKL, pro-inflammatory cytokine-mediated activation of osteoclasts, and increased SMURF1 
activity.1,2,3,4 However, melatonin has been shown to reduce inflammation and bone loss by 
inhibiting the production of TNF-! and IL-1 mRNA, and preventing RANKL and SMURF1 
from activating.6,7,8,9 Melatonin may also reduce reactive oxygen species and subsequent damage 
to bone by scavenging free radicals and increasing the activity of the endogenous antioxidants 
glutathione and superoxide dismutase.4,8,11 Having adequate circulating melatonin is also 
necessary for regulating a normal sleep cycle, which may be negatively affected by chronic 
inflammation and could have a detrimental impact on BMD.4,6,7 
While further research is needed to understand the exact mechanisms by which melatonin 
affects these processes, what is known is that many foods contain varying concentrations of 
melatonin and that consuming melatonin from whole foods increases plasma concentration of 
melatonin. A wide variety of plants, fermented products, and animal-sourced foods contain 
! 31 
melatonin and studies have found that consumption of vegetables and fruits containing melatonin 
increase excretion of melatonin metabolites and may increase serum antioxidant 
capacity.28,29,35,36 However, it is not known whether consuming melatonin from foods increases 
an individual’s capacity to reduce inflammation and oxidative stress, and increase BMD. 
Our target population consists of postmenopausal women, as women are at a higher risk of 
osteopenia, osteoporosis, and fractures after menopause due to declining estrogen levels.38,39 
Current nutritional recommendations for osteoporosis focus on consuming adequate calcium, 
vitamin D, and engaging in weight-bearing exercise to prevent bone loss.39 However, these 
recommendations do not necessarily promote the growth of new bone in women who already 
have osteopenia or osteoporosis. Further, postmenopausal women are at a higher risk of having 
elevated inflammatory markers, reduced synthesis of endogenous melatonin, and disrupted 
circadian rhythm, which could increase the risk of bone loss in this lifestage group.40,41,42,43,2,4,9 
Recent studies have indicated that melatonin supplementation has the potential to increase BMD 
in postmenopausal women without detrimental side effects.8,9,44 This led us to focus on whether 
consumption of melatonin from whole foods could be a potential therapeutic mechanism for 
reducing inflammation, regulating sleep cycles, and promoting healthy BMD in postmenopausal 
women. The goal of the current research was to conduct a cross-sectional analysis of NHANES 
data to investigate whether dietary-derived melatonin is associated with inflammatory markers, 
femur BMD, and hours of sleep.        
 
 
 
! 32 
Data Reduction and Statistical Analysis  
 Our total sample size was 110 with 55 subjects in each inflammatory group. We conducted a 
factor analysis in SPSS to reduce the dimensionality of the dataset and to identify key variables 
responsible for the majority of the variation observed between the chronic inflammatory and 
low/normal inflammatory groups. One round of factor analysis was completed. The analysis 
included all dietary, biochemical, BMD, and lifestyle factors of interest (Appendix A). We chose 
to retain four factors within our analysis, each of which had an Eigenvalue greater than 1.0 and 
together accounted for 56% of the variance in the data (Appendix B). After evaluating each 
factor analysis plot, we determined that factors 1, 2 and 3 best distinguished the variation 
between each inflammatory group because this model provided the best visual separation 
between members of each group.  
 Positive and negative factor loadings of greater than 0.50, regardless of direction, were used 
to select variables most strongly associated with factors 1, 2 and 3. However, we also considered 
variables with a factor loading of greater than 0.30 to account for biological significance. Factor 
1 explained 27.9% of the variance between the chronic and low inflammatory groups, which was 
strongly correlated with magnesium, vitamin B6, protein, folate, calories, zinc, vitamin C, 
melatonin, vitamin B12, and HDL cholesterol, with a weak correlation with CRP (Appendix B). 
Factor 2 explained 10.7% of the variance between each group and the variables HDL cholesterol, 
alkaline phosphatase, vitamin C, melatonin, zinc, calories, protein, and CRP exhibited the 
strongest correlation (Appendix B). Factor 3 explained 9.3% of the variance with CRP, hours of 
sleep, vitamin C, femur BMD, and vitamin B12 being strongly correlated (Appendix B).  
 After assessing the results of the factor analysis, we conducted a discriminant function 
analysis in SPSS to create an additional predictive model to further separate the chronic and low 
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inflammatory groups (Appendix C). CRP was removed from this analysis as it was originally 
used to separate study participants into the chronic and low inflammatory groups. This made the 
variable collinear with other variables in such a way that it violated the assumptions of 
multivariate analysis. This rationale also validated the removal of CRP from the discriminant 
function analysis, which enabled us to better assess the contribution of the other dietary, 
biochemical, and lifestyle variables to differences between each inflammatory group. In addition, 
we removed sedentary time from the dataset, as 33 individuals in the dataset had missing values 
for this variable. Removing this variable allowed us to include the majority of study participants 
in our analysis.  
 We conducted means tests in SAS on the significant variables identified from factor analysis 
and discriminant function analysis to analyze the differences between the chronic inflammatory 
and low inflammatory groups (Appendix D). Several variables had non-normal distributions. 
Melatonin, HDL cholesterol, vitamin C, magnesium, and zinc were log10-transformed and 
alkaline phosphatase was 1/x-transformed to obtain a normal distribution. We attempted to 
normalize CRP but were unable to accomplish this due to the highly skewed distribution of the 
data. Therefore, a non-parametric ANOVA was used for CRP, as this test is robust at assessing 
statistical significance in a skewed dataset. In addition, a non-parametric ANOVA was 
performed on hours of sleep, as this data also followed a non-normal distribution. T-tests were 
used to evaluate the means of femur BMD, caloric intake, and vitamin C. Non-parametric 
ANOVAs were used to assess the means of alkaline phosphatase, HDL cholesterol, melatonin, 
protein, folate, vitamin B12, vitamin B6, magnesium, zinc, sedentary time, and hours of sleep to 
account for differences in sample size between the two inflammatory groups. The sample size 
differences were due to missing data in the original dataset or from outliers that were removed 
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during analysis. Outliers were excluded if their values were less than or greater than two standard 
deviations from the mean. Variables with excluded outliers included melatonin, alkaline 
phosphatase, HDL cholesterol, calories, protein, folate, vitamin B12, vitamin B6, magnesium, 
zinc, sedentary time, and sleep.  
 We next ran a series of simple linear regressions between CRP and the selected dietary, 
biochemical, BMD, and lifestyle variables (Appendix E). By plotting the regressions between 
each group, we were able to characterize the relationship of each variable to level of 
inflammation and how variables responded differently within each inflammatory group. Multiple 
linear regression was also performed using SAS on all variables, including the variables 
excluded through factor analysis and discriminant function analysis, to explore the interactions 
between inflammatory markers, dietary components, BMD, and lifestyle factors (Appendix F).  
 Based on the results from the multiple linear regression, we created path analysis plots in the 
AMOS (Analysis of a Moment Structures) module of SPSS for both the chronic and normal 
inflammatory groups (Appendix G). AMOS is used for Structural Equation Modeling (SEM), 
path analysis, analysis of covariance, and confirmatory factor analysis. After identifying 
significant and borderline significant relationships in the multiple linear regression output, we 
created equations within each inflammatory group to represent the variables that would explain 
the variance for the variables melatonin, CRP, alkaline phosphatase, HDL cholesterol, femur 
BMD, protein, and sleep. For example, within the chronic inflammatory group, the variables 
significantly correlated with melatonin included folate, protein, magnesium, and zinc which was 
represented by Melatonin = Folate x Protein x Magnesium x Zinc. These equations were used to 
create a map to graphically represent relationships between variables in each group. We then 
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used bootstrap analysis to develop regression weight estimates for each path that predicted the 
degree of change in the response variables with every one unit change in the predictor variables.         
 Finally, the percent contribution of melatonin obtained from each food group were calculated 
to examine how different foods contribute to total melatonin intake. We included the food groups 
of fruit, vegetables, grains, dairy, and nuts and seeds, and calculated percentages within the 
chronic and normal inflammatory groups.     
 
Results 
The results from the factor analysis are displayed graphically in Figure 3. Factors 1, 2 and 3 were 
included in the analysis, as they provided the best separation and explanation for variation 
between the chronic inflammatory and low inflammatory groups. We compared the significant 
variables that had the highest loadings for each factor with the subsequent means and 
nonparametric test results. We found that participants of the low inflammatory group were 
distinguished from individuals with chronic inflammation by consuming higher levels of 
magnesium, B vitamins, protein, calories, zinc, vitamin C, and melatonin, and by having higher 
femur BMD and HDL cholesterol, and lower alkaline phosphatase. The chronic inflammatory 
group was best distinguished by having greater mean CRP, more hours of sleep, and lower 
dietary zinc, caloric intake, protein, and vitamin C (Figure 3).  
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Figure 3. Graphical representation of factor 1 vs factor 2 vs factor 3 from factor analysis with 
associated variables on each axis. Variable factor loadings of > 0.3 were considered significant. 
Factor 1 is associated with micronutrient intake (magnesium, vitamin B6, protein, folate, energy, 
zinc, vitamin C, melatonin, vitamin B12) and HDL cholesterol on positive end and increased 
inflammation on the negative end. Factor 2 is associated with high CRP and low macronutrient 
intake (energy, protein, zinc) on the negative end and low inflammation (high HDL, low alkaline 
phosphatase) and high antioxidant intake (vitamin C, Melatonin) on the positive end. Factor 3 is 
associated with increased CRP and sleep, and low vitamin C intake on the positive end, and high 
femur BMD on the negative end.      
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 Discriminant function analysis revealed that the ANOVA variables contributing a significant 
amount of prediction to separate the chronic and low inflammatory groups included folate, 
magnesium, HDL cholesterol, and melatonin (Appendix C). The analysis revealed that folate is 
the most important variable for discrimination between the groups (p = 0.001). One discriminant 
function was included, as the associated chi-square test indicated that this function best separated 
the chronic and low inflammatory groups (p = 0.001). Standardized canonical discriminant 
function revealed the variables with the highest coefficients that had the greatest ability to 
discriminate between the two groups, which included folate, vitamin B6, magnesium, calories, 
protein, melatonin, and vitamin C (Appendix C). 
 We used means tests, including t-tests and nonparametric ANOVAs, to characterize 
differences in variable means between the chronic inflammatory and low inflammatory groups 
(Table 2). Variables with significant differences between group means included CRP, HDL 
cholesterol, femur BMD, dietary melatonin, folate, vitamin B6, and magnesium. Individuals 
exhibiting chronic inflammation had significantly higher CRP and significantly lower HDL 
cholesterol, femur BMD, dietary melatonin, folate, vitamin B6, and magnesium than subjects 
with low inflammation. While the difference in mean alkaline phosphatase between the two 
groups was not significant, the borderline significant p-value indicates that alkaline phosphatase 
may still be of biological significance in these two populations.  
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Table 2. Statistical output of t-tests and nonparametric ANOVAs comparing mean values 
between the low and chronic inflammatory groups. A p-values of <0.05 was considered 
statistically significant. * denotes statistically significant variables, † denotes untransformed data 
was used to derive the mean.  
 
 Simple linear regression was conducted on variables identified in factor analysis that 
provided a significant contribution to the graphical model and significant variables identified by 
discriminant function analysis. This included HDL cholesterol, alkaline phosphatase, femur 
BMD, melatonin, energy, protein, folate, B6, B12, vitamin C, magnesium, zinc, sleep. HDL 
cholesterol exhibited a non-significant negative relationship with CRP in the low inflammatory 
group, as well as in the chronic inflammatory (Figure 4). Alkaline phosphatase showed no 
relationship to CRP in both inflammatory groups (Figure 5). 
 
 
 
Means&Test&Statistics&
Variable N Chronic&Inflammation&(M) Low&Inflammation&(M)& t;value F;value p&
CRP&(mg/dL) 110 3.43 0.42 . 146.95 <+0.0001*
Alkaline&Phosphatase&(U/L) 106 81.33† +75.49†+ . 2.89 0.092
HDL&(mg/dL) 107 54.33† +59.66†+ . 5.52 0.021*
Femur&BMD&(g/cm2) 110 0.84 0.9 02 . 0.049*
Melatonin&(ng) 109 958.33† +972.04†+ 02.15 . 0.034*
Total&Energy&(kcal) 108 1625 1690 . 0.39 0.53
Protein&(g) 109 63.34 66.83 . 0.69 0.41
Folate&(mcg) 109 293.38 390.3 04.09 . <+0.0001*
Vitamin&B6&(mg) 105 1.4 1.77 . 12.87 0.0005*
Vitamin&B12&(mcg) 103 4.03 4.5 . 1.52 0.22
Vitamin&C&(mg) 110 79.92† 84.83† 01.37 . 0.17
Magnesium&(mg) 109 229.5† 283.41† . 12.84 0.0005*
Zinc&(mg) 109 8.99† 9.98† . 2.53 0.12
Sleep&(hours) 107 7.04 6.94 . 0.12 0.73
Sedentary&Time&(min/day) 77 311.71 330 . 0.28 0.59
! 39 
 
 
 
 
 
 
 
 
Figure 4. Simple linear regression comparing untransformed HDL cholesterol to CRP in both 
low and chronic inflammatory individuals (n = 107). The orange shaded region represents 
individuals with chronic inflammation. The regression equation for both inflammatory 
groups(normal and chronic) combined was borderline significant [b=-1.46, R2=0.039, F (1,106) 
= 3.36, p=0.07,] but explained less than 4% of the observed variation in HDL. Individual 
regression equations for each group were also not significant (Normal group, ln transformed 
data, b = -0.11, R2 = 0.05, F(1, 51) = 2.48, p = 0.12 and chronic group, ln transformed data b = - 
0.01, R2 = 0.01, F(1, 52) = 0.30, p = 0.59). Data for each inflammatory group were log-
normalized as the smaller sample size produced non-normal distributions.! 
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Figure 5. Simple linear regression comparing untransformed alkaline phosphatase to CRP in low 
and chronic inflammatory individuals (n = 106). The orange shaded region represents individuals 
with chronic inflammation. The regression equation for both inflammatory groups (normal and 
chronic) combined was not significant [b=0.003, R2=6.49-08F (1,105)= 5.45 E-06, p=0.998]. 
Individual regression equations for each group were also not significant. (Normal group, ln 
transformed data, b = -0.0007, R2 = 0.009, F(1, 49) = 0.43, p = 0.5 and chronic group ln 
transformed data, b = 0.00008, R2 = 0.002, F(1, 53) = 0.12, p = 0.73. Data for each inflammatory 
group were log-normalized as the smaller sample size produced non-normal distributions. 
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 Femur BMD also exhibited different linear relationships between the normal and chronic 
inflammatory groups. Subjects with chronic inflammation showed reduced BMD with increasing 
CRP that was statistically significant, while femur BMD in subjects with low inflammation had 
an unexpected positive trend with CRP that approached statistical significance (Figure 6). 
Additional plots of simple linear regression between CRP and dietary melatonin, calories, 
protein, folate, B12, B6, vitamin C, magnesium, zinc, and hours of sleep are in Appendix E.      
 
 
Figure 6. Simple linear regression of femur BMD and CRP in low and chronic inflammatory 
individuals (n = 110). Normal group b = 0.09, R2 = 0.05, F(1, 53) = 2.96, p = 0.09 and chronic 
group b = -0.02, R2 = 0.07, F(1, 53) = 4.25, p = 0.04. 
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 We also conducted multiple linear regression to analyze the relationships between all 
variables of interest within each group (Table 3 and Table 4). Within the chronic inflammatory 
group, CRP and femur BMD showed a significant negative correlation, which was expected, but 
no dietary components were related to BMD (Table 3). HDL cholesterol and magnesium shared 
a positive relationship and melatonin was significantly correlated with a number of nutrients, 
including protein, folate, vitamin B12, magnesium, and zinc. Total caloric intake and protein 
shared a positive correlation with one other and with the majority of the nutrients included in the 
analysis. The majority of the B vitamins and minerals showed significant positive correlations 
with one another and vitamin C was related to intake of magnesium and vitamin B6. Hours of 
sleep exhibited a positive relationship with CRP, which was also observed in our simple linear 
regression.   
 Among individuals with low inflammation, more variables showed a significant relationship 
with HDL cholesterol than in the chronic inflammatory group. Alkaline phosphatase, caloric 
intake, and magnesium were all positively correlated with HDL cholesterol while sedentary time 
had a negative correlation (Table 4). BMD shared a significant positive correlation with protein 
intake, but melatonin consumption had an unexpected negative relationship to vitamin B12 
intake. As with the chronic inflammatory group, calories and protein shared a positive 
relationship, and the majority of the nutrients included in our dataset were significantly 
correlated with one another. Again, vitamin C shared a positive correlation with magnesium and 
vitamin B6. Hours of sleep shared a positive relationship with zinc consumption.    
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Table 3. Correlation coefficient matrix of all biomarkers, BMD, dietary, and lifestyle variables for the chronic inflammatory group. (Significant correlations in bold).  
  C_Reactive_Protein
Alkaline_Phosph
atase__1_x_norm
al
HDL_ln_norma
lized
Femur_
BMD
Melatonin__ln_
normal_
Energy Protein Folate B12 B6 Vitamin_C_ln Magnesium_l
n
Zinc_ln Sedenta
ry_Time
0.0484
0.7256
55
)0.07598 0.139
0.585 0.3161
54 54
!0.27237 )0.11374 0.11296
0.0442 0.4083 0.4161
55 55 54
0.0579 0.12765 0.17968 0.00489
0.6745 0.353 0.1936 0.9717
55 55 54 55
0.04466 )0.01291 0.11569 )0.02051 0.24156
0.7485 0.9262 0.4048 0.883 0.0785
54 54 54 54 54
0.10089 0.16767 0.0185 0.11879 0.36845 0.67503
0.4636 0.2211 0.8944 0.3877 0.0056 <.0001
55 55 54 55 55 54
0.05545 0.09674 0.13139 )0.01763 0.45998 0.58513 0.58957
0.6905 0.4865 0.3483 0.8993 0.0005 <.0001 <.0001
54 54 53 54 54 53 54
0.17797 )0.00914 )0.02727 )0.03622 0.30769 0.4926 0.65134 0.59154
0.2115 0.9493 0.8493 0.8008 0.0281 0.0002 <.0001 <.0001
51 51 51 51 51 51 51 50
)0.05872 0.20769 0.0619 0.08674 0.22505 0.42603 0.60559 0.61384 0.58582
0.6823 0.1436 0.6693 0.545 0.1123 0.002 <.0001 <.0001 <.0001
51 51 50 51 51 50 51 50 48
0.26037 0.09834 0.22949 0.09547 0.08713 0.11573 0.13894 0.25055 0.24382 0.33132
0.0549 0.475 0.0951 0.4881 0.5271 0.4046 0.3117 0.0676 0.0847 0.0176
55 55 54 55 55 54 55 54 51 51
0.18302 0.26722 0.27846 0.02641 0.52804 0.59664 0.63194 0.67885 0.56189 0.70229 0.47248
0.1853 0.0508 0.0435 0.8496 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 0.0003
54 54 53 54 54 53 54 53 50 50 54
0.01683 0.15956 0.08441 )0.0069 0.47376 0.59904 0.83769 0.72572 0.6916 0.58183 0.16732 0.68969
0.9038 0.2491 0.5479 0.9605 0.0003 <.0001 <.0001 <.0001 <.0001 <.0001 0.2265 <.0001
54 54 53 54 54 53 54 53 51 50 54 53
0.04292 0.1429 )0.2129 0.04567 )0.24209 )0.1758 )0.19338 )0.24928 )0.14053 )0.1908 )0.24684 )0.29647 )0.29099
0.7899 0.3728 0.1814 0.7768 0.1273 0.2716 0.2257 0.1209 0.3935 0.2512 0.1197 0.0632 0.0649
41 41 41 41 41 41 41 40 39 38 41 40 41
0.27569 )0.03755 )0.0655 )0.1458 0.03155 )0.1114 )0.00411 )0.01312 0.12295 0.10043 0.08146 0.00353 0.05723 0.19483
0.0457 0.7895 0.6446 0.2975 0.8225 0.4317 0.9767 0.9264 0.395 0.4877 0.562 0.9802 0.687 0.2346
53 53 52 53 53 52 53 52 50 50 53 52 52 39
Zinc_ln
Sedentary_Time
Sleep__hours_
Protein
Folate
B12
B6
Vitamin_C_ln
Magnesium_ln
Energy
C_Reactive_Protein
Alkaline_Phosphata
se__1_x_normal
HDL_ln_normalized
Femur_BMD
Melatonin__ln_nor
mal_
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Table 4. Correlation coefficient matrix for all biomarkers, BMD, dietary, and lifestyle variables for the normal inflammatory group. (Significant correlations in bold).
C_Reactive_Protein Alkaline_Phosp
hatase__1_x_n
ormal
HDL_ln_norma
lized
Femur_BMD Melatonin__ln_
normal_
Energy Protein Folate B12 B6 Vitamin_C_ln Magnesium_ln Zinc_ln Sedentary_T
ime
!0.09364
0.5134
51
!0.21518 0.31909
0.1218 0.0254
53 49
0.23003 !0.04689 !0.08556
0.0911 0.7439 0.5424
55 51 53
0.12909 0.15652 !0.10948 !0.10334
0.3522 0.2777 0.4398 0.4571
54 50 52 54
0.01332 !0.15817 0.34492 0.21217 !0.26644
0.9238 0.2726 0.0123 0.1235 0.0538
54 50 52 54 53
0.03411 !0.1085 0.19866 0.30197 !0.05829 0.61902
0.8066 0.4532 0.158 0.0265 0.6785 <.0001
54 50 52 54 53 53
0.06189 0.18769 0.06063 0.10504 0.00322 0.34051 0.23636
0.6535 0.1872 0.6663 0.4454 0.9816 0.0118 0.0853
55 51 53 55 54 54 54
0.04054 !0.02368 0.11404 !0.0039 -0.30598 0.32026 0.39583 0.51549
0.7754 0.8731 0.4304 0.9781 0.029 0.022 0.004 <.0001
52 48 50 52 51 51 51 52
0.09081 0.11964 0.01704 0.0516 0.04173 0.32206 0.42873 0.55438 0.55633
0.5137 0.4079 0.9046 0.711 0.7667 0.0187 0.0014 <.0001 <.0001
54 50 52 54 53 53 53 54 51
0.02511 0.08055 0.11143 !0.02668 0.26109 0.09988 0.05801 0.35847 0.04735 0.38013
0.8556 0.5742 0.427 0.8467 0.0565 0.4724 0.677 0.0072 0.7389 0.0046
55 51 53 55 54 54 54 55 52 54
0.05324 0.02184 0.28744 0.18597 0.05128 0.6311 0.6753 0.4699 0.30258 0.50111 0.31981
0.6995 0.8791 0.0369 0.174 0.7127 <.0001 <.0001 0.0003 0.0292 0.0001 0.0173
55 51 53 55 54 54 54 55 52 54 55
0.12917 0.02539 0.22784 0.21281 0.00614 0.68503 0.7397 0.37983 0.3964 0.44631 0.0967 0.63893
0.3473 0.8596 0.1008 0.1188 0.9649 <.0001 <.0001 0.0042 0.0036 0.0007 0.4825 <.0001
55 51 53 55 54 54 54 55 52 54 55 55
0.27207 !0.04074 -0.35837 0.20509 0.22199 !0.08809 0.16676 0.05604 0.00596 0.12162 0.08511 0.2584 0.14729
0.1084 0.8219 0.0345 0.2302 0.2 0.6148 0.3383 0.7455 0.9729 0.4798 0.6217 0.1281 0.3913
36 33 35 36 35 35 35 36 35 36 36 36 36
0.19498 !0.05441 !0.00201 !0.0586 0.04008 0.14648 0.19315 0.21685 0.2048 0.09264 0.15137 0.17281 0.27324 !0.07199
0.1577 0.7074 0.9887 0.6738 0.7757 0.2953 0.1658 0.1153 0.1494 0.5094 0.2746 0.2114 0.0456 0.6765
54 50 52 54 53 53 53 54 51 53 54 54 54 36
Zinc_ln
Sedentary_Time
Sleep__hours_
Protein
Folate
B12
B6
Vitamin_C_ln
Magnesium_ln
Alkaline_Phosphat
ase__1_x_normal
HDL_ln_normalize
d
Femur_BMD
Melatonin__ln_nor
mal_
Energy
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 The path analysis revealed a number of differences between the chronic and normal 
inflammatory groups in variable correlations and predictive relationships (Figure 7 and Figure 
8). Within the chronic inflammatory group, CRP, femur BMD, melatonin, and dietary protein 
were included as predictive variables (Figure 7). With regards to CRP, hours of sleep was a 
significant positive predictor and folate was a significant negative predictor. CRP was a 
significant negative predictor of femur BMD. Magnesium and zinc were significant positive 
predictors of dietary melatonin and protein intake was negatively correlated with melatonin. 
Protein intake was negatively predicted by folate, and positively predicted by caloric intake, 
vitamins B12 and B6, melatonin, and zinc.  
 In the normal inflammatory group, the variables CRP, hours of sleep, HDL cholesterol, 
femur BMD, melatonin, and protein were identified as predictive variables in the model (Figure 
8). However, there were fewer statistically significant relationships identified in the normal 
inflammatory group with caloric intake, vitamin B6, and zinc being positive predictors of protein 
intake.   
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Figure 7. Path analysis of chronic inflammatory group multiple linear regression variables. 
Arrow numbers indicate regression weights that define the degree to which the response variable 
changes with every one unit increase in the predictor variable. * indicates significant 
relationships. 
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* * 
* 
* 
* 
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Figure 8. Path analysis of normal inflammatory group multiple linear regression variables. 
Arrow numbers indicate regression weights that define the degree to which the response variable 
changes with every one unit increase in the predictor variable. * indicates significant 
relationships. 
* 
* 
* 
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 Finally, we calculated the percent contribution of each food group to the total melatonin 
consumed in each group (Figures 9 and Figure 10). Grain products constituted the majority of 
dietary melatonin in both the chronic and low inflammatory groups. Fruits and vegetables 
provided the next greatest percent contribution, with nuts and dairy providing the least. While 
individuals in the normal inflammatory group consumed a significantly greater amount of 
melatonin than individuals in the chronic inflammatory group, less of their dietary melatonin was 
consumed from fruits and vegetables with a greater percentage from grains compared to the 
chronic inflammatory group.  
Figure 9. Percent contribution of each food group to the total melatonin consumed by 
individuals in the chronic inflammatory group.  
Fruit
6%
Vegetables
6%
Grains
86%
Dairy
1%
Nuts!&!Seeds
1%
! 49 
 
Figure 10. Percent contribution of each food group to the total melatonin consumed by 
individuals in the normal inflammatory group. 
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Discussion  
Nutrients and Endogenous Melatonin Synthesis 
 The results from the factor analysis revealed key dietary, inflammatory, and lifestyle factors 
that distinguished the normal and chronic inflammatory groups from one another. A notable 
result was that individuals with low CRP exhibited the highest intake of B vitamins and minerals 
that are important for endogenous production of melatonin. The low inflammatory group 
consumed significantly greater amounts of folate, vitamin B6, and magnesium than those with 
chronic inflammation. The low inflammatory group also had a higher, although not statistically 
significant, intake of vitamin B12, vitamin C, and zinc. Folate is a coenzyme for TPH and 
provides methyl groups for the final step of the pathway where HIOMT converts N-
acetylserotonin to melatonin (Figure 1). Vitamin B6 is a coenzyme for AADC in the endogenous 
pathway and B12 is needed in the folate cycle to allow methionine synthase to obtain methyl 
groups from folate, which would then be passed to HIOMT (Figure 1). Further, zinc and 
magnesium are required cofactors for AANAT, which converts serotonin to N-acetylserotonin 
(Figure 1). Since the chronic inflammatory group consumed less of these nutrients, it is possible 
that a lack of cofactors and coenzymes might prevent or decrease the activity of the endogenous 
melatonin pathway. Reduced synthesis of endogenous melatonin would reduce the beneficial 
effects of melatonin on inflammation, oxidative stress, and circadian rhythm. A lack of 
endogenous melatonin could also limit synthesis of new bone, since melatonin has the ability to 
stimulate osteoblasts, and unchecked inflammation and oxidative stress could negatively impact 
BMD by stimulating bone resorption.  
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Folate and Melatonin Synthesis 
 The discriminant function analysis revealed that folate was of the nutrient of greatest 
importance in differentiating the low and chronic inflammation groups. Folate consumption 
showed a significant positive correlation with melatonin consumption in the chronic 
inflammatory group as evidenced by multiple linear regression analysis. Means tests, however, 
showed that the low inflammatory individuals consumed significantly more folate overall than 
those with chronic inflammation. The significance of this result is highlighted by the 
physiological role of folate as a methyl donor that allows S-adenosyl-methionine to deliver a 
methyl group to N-acetylserotonin to create melatonin (Figure 1). In an animal model of folate 
deficiency, rats that did not consume folate over a 4-week period had significantly reduced 
melatonin concentration in the pineal gland, as well as reduced excretion of 6-SMT in the urine, 
compared to animals that consumed adequate melatonin.52 The authors suggested that reduced 
melatonin synthesis due to folate deficiency could contribute to a number of health problems, 
since melatonin is important for regulating inflammation and ROS.52 Another study evaluated 
the effects of melatonin and folic acid supplementation in an animal model of oxidative stress 
and inflammation.53 When rats were provided with either melatonin, folic acid, or a combination 
of both, there was a greater improvement in parameters associated with cellular damage and 
antioxidant activity with the combined melatonin and folic acid treatment.53 Therefore, folate and 
melatonin may work synergistically to control inflammation and oxidative stress, where methyl 
groups from folate enhance endogenous melatonin production and increase melatonin synthesis, 
combined with exogenous melatonin supplementation, would provide an improved ability to 
mitigate inflammation and ROS. Furthermore, since melatonin is primarily found in plant foods, 
such as fruits, vegetables, and whole grains, that are good sources of folate, individuals who 
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consume more of these foods would also obtain more dietary melatonin. This is one plausible 
theory that could explain why folate appeared as the variable of primary importance in the 
discriminant function analysis.     
 
Vitamin B12 and Melatonin Synthesis 
 While mean vitamin B12 consumption did not differ significantly between each 
inflammatory group, B12 consumption showed a significant positive correlation with melatonin 
consumption in the chronic inflammatory group and significant negative correlation in the 
normal inflammatory group in the multiple linear regression. Vitamin B12 is a necessary 
component of the folate cycle to allow methyl groups from folate to be passed to N-
acetylserotonin (Figure 1). However, B12 and folate are typically obtained from different food 
groups. Since B12 is primarily found in animal foods and melatonin in plant foods, individuals 
of the normal inflammatory group who consumed fewer animal products rich in vitamin B12 and 
more plant foods rich in melatonin could have contributed to the apparent negative correlation. 
This result may also be a function of individuals in the chronic inflammatory group consuming 
greater amounts of meat than the normal group while attempting to increase intake of fruits and 
vegetables, which is medical advice that would be common for most diseases of inflammation 
(e.g., obesity, heart disease, cardiovascular problems, diabetes, cancer, etc). It is also possible 
that individuals with chronic inflammation consuming more dietary melatonin are more likely to 
obtain vitamin B12 through supplements, fortified foods, and meal replacements that contain 
large amounts of B12.   
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 This result is of interest as there is evidence that B12 is an important component for adequate 
endogenous melatonin release. In a rat model of circadian rhythm, an injection of methyl-B12 
prior to taking samples from the pineal gland resulted in a significant increase in melatonin 
secretion.54 The authors of this study ascertained that vitamin B12 both increased endogenous 
synthesis and secretion of melatonin while elevating the sensitivity of the rat circadian clock to 
the effects of melatonin.54 An additional study examined vitamin B12 supplementation in 
humans and found that urinary excretion of the melatonin metabolite, 6-SMT, peaked during the 
night following vitamin B12 supplementation.55 Further, individuals taking a methylcobalamin 
supplement tended to have improved sleep and more alertness upon waking.55 While more 
information is needed to understand the exact role of vitamin B12 in melatonin synthesis and 
sleep cycles, it is plausible that inadequate B12 consumption could compromise melatonin 
production, therefore limiting the ability of melatonin to reduce inflammation, oxidative stress, 
and to promote bone health.  
 
Vitamin B6 and Melatonin Synthesis 
Vitamin B6 consumption was significantly higher in the normal group than in the chronic 
inflammatory group with no significant correlations observed through multiple linear regression. 
Although B6 is a coenzyme for the pathway of endogenous melatonin synthesis, limited research 
has examined its effects on melatonin production. One study found no significant increase in 
serum melatonin levels after supplementation with vitamin B6 compared to a placebo in adult 
males.56 However, other research has found that pyridoxine deficiency causes a significant 
decrease in melatonin production in rats.57 Pyridoxine deficiency negatively altered the activity 
of 5-hydroxytryptophan decarboxylase, also known as AADC, which resulted in a buildup of 5-
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hydroxytryptophan and a reduction in 5-hydroxytrytamine or serotonin.57 Although this study 
was performed in animals, vitamin B6 deficiency may have the potential to alter melatonin 
synthesis and prevent melatonin from exerting its beneficial effects on inflammation, oxidative 
stress, and BMD.   
 
Magnesium, Zinc and Melatonin Synthesis 
Magnesium and zinc exhibited significant positive correlations with dietary melatonin in the 
chronic inflammatory group. Similar to previously described dietary patterns, the normal 
inflammatory group consumed significantly more magnesium than the chronic group. 
Magnesium and zinc were also significant predictors of melatonin intake in the path analysis of 
individuals with chronic inflammation. Foods that are good sources of magnesium and zinc, such 
as whole grains, nuts, seeds, and dairy also contain significant levels of melatonin, contributing 
to the observed positive correlations. A few studies have explored how magnesium and zinc are 
related to melatonin production and circadian rhythm. An animal model of magnesium 
deficiency found that after four weeks of consumption of a magnesium-deficient diet, rats had a 
significant reduction in plasma melatonin concentration compared to the animals receiving an 
appropriate amount of dietary melatonin.58 The authors suggested that since magnesium is a 
required cofactor for the enzyme AANAT, which converts serotonin to N-acetylserotonin, 
inadequate dietary magnesium could negatively affect the ability of this pathway to function.58 A 
double-blind, randomized controlled trial evaluated the effects of daily supplemental magnesium, 
zinc, and melatonin on insomnia and quality of sleep in long-term care facility residents.59 It was 
found that study participants supplemented with 225 mg magnesium, 11.25 mg zinc, and 5 mg 
melatonin had significant improvements in overall sleep quality and sleep time compared to 
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study participants receiving a placebo.59 However, it is difficult to ascertain whether the 
supplemental melatonin, magnesium and zinc, or both increased serum melatonin and resulted in 
improved circadian rhythm. Based on these studies, magnesium and zinc have the potential to 
enhance endogenous synthesis of melatonin and to improve outcomes of melatonin on sleep, 
inflammation and BMD. However, more studies are needed to evaluate the separate and 
combined effects of supplemental magnesium and zinc on endogenous melatonin production, 
and whether inadequate intake has a negative impact on serum melatonin in humans.    
 
Calories, Protein, and Melatonin Synthesis 
 Although not statistically significant, the low inflammatory group consumed more calories 
and protein than those with chronic inflammation. Protein, however, was significantly correlated 
with melatonin in individuals with chronic inflammation. Increased protein levels would be 
beneficial for endogenous melatonin production through metabolic pathways related to 
tryptophan. Calorie restriction may significantly reduce blood concentration of melatonin; in this 
circumstance, adequate tryptophan would be necessary to serve as the starting substrate for 
melatonin production.5 A lack of both calories and protein could therefore interfere with 
endogenous melatonin synthesis in the chronic inflammatory group. Furthermore, consuming an 
inadequate amount of calories would make it difficult to obtain optimal amounts of the vitamins 
and minerals necessary for endogenous production of melatonin. Since melatonin is involved in 
reducing inflammation by inhibiting nuclear factor-!", TNF-#, and IL-1, consuming adequate 
amounts of nutrients needed for optimal endogenous melatonin production is important.6,7,8,9  
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Tryptophan, Niacin, and Melatonin 
 It is important to note that some tryptophan, which is the starting substrate for melatonin 
synthesis, is converted to niacin (Figure 1). Therefore, not all dietary tryptophan is directed to the 
pathway of endogenous melatonin synthesis. If an individual is niacin deficient, it is possible that 
more tryptophan would be diverted away from the pathway of endogenous melatonin synthesis 
to produce additional niacin. This would limit the amount of endogenous melatonin produced 
and could lead to excess inflammation, oxidative stress, reduced BMD, and disrupted circadian 
rhythm that would be mitigated under conditions of normal melatonin synthesis. This situation 
would make dietary melatonin of even greater importance to compensate for a lack of 
endogenous melatonin. Although this study did not evaluate niacin consumption of study 
participants, it would be important to assess the relationship between niacin, tryptophan, and 
dietary and endogenous melatonin to better understand how the pathways of tryptophan 
metabolism are prioritized within the body.     
 
Dietary Melatonin Consumption 
 Mean dietary melatonin consumption was significantly higher in the normal group, was an 
important variable in the initial factor analysis, and melatonin consumption was predicted by a 
number of nutrients in the path analysis. However, we did not find significant direct associations 
between dietary melatonin and femur BMD, inflammatory markers, or hours of sleep. It is 
possible that melatonin did not explain the majority of variation in our outcome variables of 
interest because melatonin may work with other nutrients to mitigate inflammation and oxidative 
stress, rather than functioning on its own. Melatonin was significantly correlated with other 
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nutrients, such as protein, folate, B12, magnesium, and zinc, which means that melatonin may be 
obtained from foods that also contain these nutrients. While melatonin has its own unique 
functions of promoting BMD, regulating circadian rhythm, and reducing inflammation and ROS, 
its actions may be enhanced by the presence of other important nutrients where melatonin is one 
key player in the overall pathway of reducing inflammation and oxidative stress, and improving 
bone health.  
 Dietary melatonin and the foods that contain nutrients important for melatonin synthesis 
should be considered from an integrative perspective in that no single food source is the best at 
providing melatonin. Nutrients are not single components that act alone; rather, they interact 
with one another to improve health via synergistic mechanisms.60,61 It is therefore likely that any 
positive health effects of dietary melatonin occur through its interactions with other nutrients. 
Further, having a deficiency in a single nutrient could reduce the effectiveness of dietary 
melatonin if the absent nutrient is needed to enable melatonin to perform its metabolic 
functions.60,61 This therefore supports consumption of a diet containing a variety of foods rich in 
melatonin to ensure that the array of nutrients needed for melatonin metabolism are present. The 
idea of food synergy also suggests that isolated sources of melatonin from supplements, without 
the presence of synergistic nutrients, may not be as effectively utilized within the body as 
melatonin from whole foods.      
  
Nutrients and BMD: Protein  
The differences in nutrient consumption between each inflammatory group complement our 
findings on femur BMD. Individuals with low inflammation had significantly higher femur 
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BMD than those with chronic inflammation, which may be associated with having greater mean 
consumption of a number of the nutrients discussed above. Protein consumption showed a 
significant positive correlation with femur BMD in the normal inflammatory group, with femur 
BMD being a positive predictor of protein intake in the path analysis of this group. Having 
adequate dietary protein intake would improve BMD in a number of ways. Protein is essential 
for promoting proper collagen matrix formation, as well as increasing levels of IGF-1, which is 
involved in activating bone growth and promoting activation of calcitriol in the kidneys to lead 
to increased dietary calcium absorption at enterocytes.62 In a prospective cohort study evaluating 
protein intake and BMD in individuals ages 50 and older, postmenopausal women consuming 
less than 12% of their total energy intake from protein had a significantly greater risk of 
developing fractures than those consuming at least 15% of total calories from protein.63 Further, 
postmenopausal women consuming protein in the lowest quartile had a significantly greater risk 
of fragility fractures than women in the second highest quartile.63 It has also been suggested that 
postmenopausal women who consume greater than 0.8 g/kg body weight of protein per day not 
only have higher BMD, but slower bone loss over time.62  
 
B Vitamins and BMD 
 Folate, vitamin B12, and vitamin B6 may also contribute to the significant differences in 
femur BMD observed between the low and chronic inflammatory groups, since the normal 
inflammatory group showed a significantly higher consumption of folate and vitamin B6 than the 
chronic group. A number of studies have examined whether supplementation with these vitamins 
has the ability to increase BMD with mixed results. Women older than 54 years were provided 
with supplementation with 500 µg folic acid, 50 mg vitamin B6, and µg 500 vitamin B12, as 
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well as vitamin D and calcium over one year, and were found to have significantly reduced 
alkaline phosphatase.64 This indicates that the B vitamins may reduce bone turnover and prevent 
bone loss in older females.64 Other studies providing B vitamin supplementation have found no 
significant impact on markers of bone turnover, which may have been due to reduced length of 
time taking the supplements and differences in quantity of each vitamin.64 A number of cohort 
studies examining folate consumption and hip fractures indicate that adequate folate status may 
be of more importance for promoting optimal femur BMD in females rather than males.64 
Limited data on vitamin B12 status and associations with BMD show a significant decrease in 
BMD with inadequate serum vitamin B12 in older women, but other studies indicate that there is 
no significant association between these two variables.64 In regards to vitamin B6, it was found 
that increased pyridoxine consumption in older adults was associated with higher femur BMD 
with another study indicating that pyridoxal-5’-phosphate may be of particular importance for 
preventing osteoporotic fractures.65  
 Research points to homocysteine and lack of vitamin B12 and folate as a possible link to less 
than optimal BMD. It is known that folate, B12, and B6 are necessary to run the folate cycle to 
prevent the buildup of homocysteine, and that elevated homocysteine leads to inflammation, 
oxidative stress, and endothelial damage.65 In vitro and animal models examining the effects of 
homocysteine have found that even slightly higher than normal concentrations of homocysteine 
lead to activation of osteoclasts, reduction in bone formation, and inhibition of protein cross-
linking that is necessary to produce a healthy bone matrix.65 Elevated homocysteine and the 
resulting damage to blood vessels has also been suggested to interfere with bone vascularization 
and delivery of nutrients necessary for building healthy bones.65 Studies in mice have found that 
those with vitamin B12 deficiencies had reduced numbers of osteoblasts and increased rates of 
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osteoporosis.65 A randomized, double-blind, placebo-controlled trial investigated whether 
supplementation with 400 µg folic acid, 500 µg vitamin B12, and 600 IU vitamin D compared to 
a control group with only 600 IU vitamin D would increase bone health in adults older than 65 
years with mild hyperhomocysteinemia.66 The authors found that after 2 years, there was a 
significant increase in BMD of the lumbar spine but a significant decrease in femoral neck 
BMD.66 However, subjects ages 80 and older were more responsive to supplementation since 
they exhibited greater calcaneal broadband ultrasound attenuation, which is an indicator of 
higher bone quality.66  
 While studies are inconclusive regarding the role of supplemental folate and vitamins B12 
and B6 on bone health, it is important to consider that habitual and long-term consumption of 
these B vitamins from whole foods could have a beneficial impact on BMD. These nutrients 
could affect BMD via multiple pathways, such as directly influencing osteoblast and osteoclast 
activity, reducing the production of homocysteine, or increasing endogenous melatonin 
production, which is known to increase bone formation and reduce bone damage caused by 
oxidative stress and inflammation.      
 
Magnesium, Zinc, and BMD 
 Magnesium and zinc consumption also appeared as important variables linked to BMD in 
factor analysis. The chronic inflammatory group had a significantly lower intake of magnesium 
as compared to individuals with low inflammation. Zinc was also a positive predictor of femur 
BMD in the normal inflammatory group path analysis, which was not statistically significant. As 
with the B vitamins, magnesium and zinc have been shown to be involved in BMD and are of 
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importance for bone health in postmenopausal women. Both are important for promoting 
formation of a healthy bone matrix, where zinc may be a necessary component of bone 
mineralization and magnesium may be involved in hydroxyapatite crystal formation and 
regulation of parathyroid hormone release.67 A cross-sectional study compared dietary intake of 
magnesium and zinc, serum magnesium and zinc, and level of femur BMD classified by either 
osteopenia or osteoporosis.67 This study found that the mean consumption of magnesium and 
zinc were below the RDA for postmenopausal women, with subjects having low femur BMD 
consuming around 48% of the RDA for zinc and 35% of the RDA for magnesium.67 Participants 
with low BMD had reduced serum zinc and 40% of the participants had low serum magnesium.67 
Therefore, it is possible that poor magnesium and zinc intake may be related to loss of BMD in 
postmenopausal women and may have contributed to the significantly reduced BMD seen in the 
chronic inflammatory group.  
 Zinc may play a larger role by influencing BMD directly, as well as through regulation of the 
immune system and chronic inflammation that are known to negatively affect bone health. Zinc 
is involved in the regulation of osteoblasts and osteoclasts, enzymatic reactions that promote 
formation of the collagen matrix and bone mineralization, and production of growth factors 
needed for bone formation.68 Zinc deficiency results in alterations of the immune system that 
favor a low-grade pro-inflammatory state, including increased activation of T-cells and 
monocytes, and elevated production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β, 
which have been shown to normalize with addition of zinc in an in vitro model of zinc 
deficiency.68 Therefore, increased production of pro-inflammatory cytokines, due to zinc 
deficiency, and inflammatory-mediated activation of osteoclasts and inhibition of osteoblasts 
would reduce BMD in individuals consuming inadequate zinc.68 In an animal model of 
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inflammation, BMD was significantly reduced in animals experiencing low-grade inflammation 
but zinc deficiency with low-level inflammation did not result in significant bone loss.68 While 
the authors concluded that a moderate zinc deficiency with inflammation would negatively affect 
bone biomechanics, it is possible that, given the important role of zinc in humans, inadequate 
zinc intake could have detrimental effects on BMD in postmenopausal women. While there was 
no significant difference in zinc intake between the low and chronic inflammatory groups in our 
study, individuals with lower mean zinc consumption had significantly higher levels of CRP, 
significantly lower HDL cholesterol and femur BMD, and borderline significantly higher levels 
of alkaline phosphatase compared to the low inflammatory group. This suggests that zinc may 
play an underlying role in regulating low-grade inflammation and promoting BMD. 
 
Outliers and Supplementation 
 It is important to note that we found some unusual patterns while normalizing our data and 
removing outliers with values greater than or less than two standard deviations from the mean. 
Several of the outliers identified in the chronic inflammatory group had nutrient intakes that were 
well above the mean. These nutrient intakes were at a level that would be difficult to obtain from 
whole foods alone, leading us to suggest that individuals with chronic inflammation may have 
been more likely to obtain nutrients from supplements rather than food. While we did not 
evaluate supplementation among subjects included in our analysis, outliers who may have 
obtained the majority of their nutrients from supplements might not be consuming other 
beneficial components of whole foods, such as dietary melatonin, that would help mitigate 
inflammation and oxidative stress.     
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Inflammatory Markers and BMD  
 In regards to the markers of inflammation, CRP concentration was significantly higher in the 
chronic inflammatory group; this was expected, as this was the variable we used to initially place 
individuals in each inflammatory group. However, CRP was also independently identified as a 
variable of importance to distinguish each inflammatory group in the factor analysis, which 
aligned with the means tests.  
 CRP was positively predicted by alkaline phosphatase and hours of sleep, and negatively 
predicted by dietary folate in the chronic inflammatory group path analysis. Elevated alkaline 
phosphatase is related to increased bone turnover and bone loss in postmenopausal women, and 
may be used as a marker of osteomalacia and osteoporosis.49 A cross-sectional study that 
assessed the ability of an osteoporosis predictive tool to identify women with osteopenia found 
that women with lower BMD had significantly higher alkaline phosphatase than women with a 
healthy BMD.50 Since chronic inflammation and elevated CRP are known to negatively affect 
BMD, it makes sense that increased alkaline phosphatase would be associated with an increase in 
CRP in the chronic inflammatory group path analysis.1,2,3 This observation was further validated 
by our finding that individuals with chronic inflammation had significantly reduced mean femur 
BMD and borderline significantly higher alkaline phosphatase compared to individuals of the 
normal inflammatory group. Multiple linear regression also revealed that CRP had a significant 
negative association with femur BMD in the chronic inflammatory group, which was identified 
as a significant relationship in path analysis and which is in agreement with literature describing 
the detrimental impact of inflammation on BMD.1,2,3 Folate consumption was a significant 
negative predictor of CRP in the chronic inflammatory group, a result that  aligns with folate’s 
role of providing methyl groups to run the folate cycle. Since elevated homocysteine leads to 
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inflammation, oxidative stress, and elevated CRP, adequate folate consumption would provide 
the methyl groups needed to convert homocysteine to methionine, therefore mitigating the 
detrimental effects of elevated homocysteine and, therefore, inflammation.65 
 While the normal inflammatory group exhibited significantly greater femur BMD, 
significantly lower CRP, significantly higher HDL cholesterol, and borderline significantly lower 
alkaline phosphatase, none of the inflammatory markers in this group were significantly 
correlated with femur BMD. In contrast, alkaline phosphatase showed a nonsignificant, negative 
correlation with HDL cholesterol in the path analysis. Since elevated alkaline phosphatase is 
associated with bone loss and possibly inflammation in postmenopausal women, and HDL 
cholesterol is an indirect marker of chronic inflammation, our observations support the negative 
association observed between these two variables in the normal inflammatory group.47,49,50   
 However, it is important to note that other studies have reported a differing role of alkaline 
phosphatase in BMD. A case-control study was performed to evaluate biochemical markers that 
can be used to predict low BMD in postmenopausal women, and found that study participants 
with osteoporosis and the highest fracture rates exhibited the lowest serum concentrations of 
alkaline phosphatase compared to control subjects with a normal BMD.51 The authors suggested 
that since alkaline phosphatase is also an indicator for bone formation, postmenopausal women 
with low levels of bone growth would be at a higher risk for osteopenia, osteoporosis, and 
fractures.51 Therefore, it is important to consider factors that could increase alkaline phosphatase 
in individuals with a normal BMD and low levels of inflammation, such as weight-bearing 
exercise that would stimulate the production of new bone.  
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Sleep and Inflammation 
 In regards to sleep, an increase in the number of hours of sleep per day was positively 
correlated with CRP in the chronic inflammatory group (multiple linear regression) and was an 
important variable for distinguishing individuals with chronic inflammation from those with low 
levels of inflammation in the factor analysis. In the path analysis, sleep was also a significant 
positive predictor of CRP in the chronic inflammatory group and CRP was a positive predictor of 
sleep in the normal inflammatory group. These results suggest that longer sleep time is 
associated with elevated markers of inflammation. A randomized-controlled trial evaluated the 
effects of longer sleep duration on pro-inflammatory cytokines and depressive symptoms in 
healthy individuals, the majority of which were women. The treatment group exposed to three 
extra hours of time in bed experienced doubled IL-6 concentration and increased parameters of 
depression, compared to control subjects that remained in bed for their usual mean sleep time.69 
An additional study evaluated associations between sleep quality and plasma markers of 
inflammation in perimenopausal and postmenopausal women.70 The authors found that increases 
in sleep disturbance exhibited a positive correlation with CRP, IL-6, a macrophage inflammatory 
protein-1", and interferon gamma-inducible protein-10.70 
  On the other hand, a cross-sectional study reported that for every one-hour decrease in 
amount of sleep at night in middle-aged men and women, CRP and IL-6 were elevated by 8.1% 
and 4.5% respectively.71 It is also plausible that excess time spent sleeping and remaining 
sedentary in bed would reduce the amount of time an individual engages in physical activity, 
which could result in elevated levels of inflammation. While our study was not able to 
effectively evaluate sleep disturbances and although there was no significant difference in mean 
hours of sleep between the chronic and normal inflammatory groups, the available literature 
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suggests that sleep either in excess of or below recommendations may contribute to a chronic 
inflammatory state. When looking at the distribution of hours of sleep in the chronic 
inflammatory group, it is clear that a number of individuals in this group have an average 
number of hours of sleep in excess of 10 hours per night, which could contribute to differences in 
inflammation and melatonin consumption between each inflammatory group (Appendix D). The 
distribution of individuals with less than six hours of sleep was similar in both the normal and 
chronic inflammatory groups (Appendix D).     
 
Sedentary Time and Inflammation 
 While average minutes of sedentary time per day was included in our factor analysis and 
multiple linear regression, there were no significant differences in mean sedentary time between 
each inflammatory group. HDL cholesterol exhibited a significant negative correlation with 
sedentary time in the normal inflammatory group, which is plausible since physical activity is a 
mechanism that increases serum HDL cholesterol. We did not find any other significant 
relationships between sedentary time and our variables of interest. This may have occurred since 
only two-thirds of the subjects included in our analysis had a value for sedentary time, as the 
NHANES physical activity questionnaires were not the same between each of the three datasets 
we used for this study. The questions asking participants about type and level of physical activity 
were also inconsistent between years of data collection. Therefore, we were unable to accurately 
quantify amount and level of physical activity or lack of physical activity among our study 
participants; this prevented us from assessing the relationship between activity level, BMD, 
inflammation, sleep, and dietary melatonin.        
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Dietary-Derived Melatonin 
 In regards to the percent contribution of each food group towards the total melatonin 
consumption, both groups obtained the majority of dietary melatonin from grains. Fruits, 
vegetables, nuts and seeds, and dairy made up the smallest percentages of overall melatonin 
intake in all cases. Much of this result was driven by how we assessed melatonin intake and 
whether there were available data to describe the effects of cooking on the melatonin content of 
these foods, since melatonin degrades with heat exposure. Grain products made up the majority 
of dietary melatonin since there was available literature describing the effects of hydrothermal 
processing on the melatonin content of these foods.30 After the highest temperature exposure of 
400° F, the grains included in the study still contained a significant concentration of melatonin 
per gram of food.30 We were only able to include raw fruits and vegetables in the average 
melatonin consumed by each individual, due to an absence of data on the melatonin content of 
cooked fruits and vegetables. Had there been studies available quantifying the degree of 
melatonin degradation in fruits and vegetables with varying amount and time of cooking, it is 
possible that we could have counted more of these foods in our analysis. This may have allowed 
produce to constitute a larger percentage of total dietary melatonin consumed by each 
inflammatory group.  
 It is also important to consider that the overall diet quality of each individual could have 
contributed to the majority of dietary melatonin being obtained from grains. Many individuals 
consumed a diet with large amounts of refined, and possibly fortified, grains that contained 
melatonin due to yeast leavening. However, an overabundance of these foods would reduce the 
nutritional quality and variety of an individual’s diet and prevent individuals from obtaining 
other nutrients that are important for maintaining BMD, endogenous melatonin production, 
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reducing chronic inflammation, and regulating sleep. Evaluating the relationship between diet 
quality and dietary melatonin intake would be a method of further evaluating the contribution of 
each food group towards total melatonin consumption. Within this study, diet quality could be 
assessed by comparing each group’s mean intake of vitamins and minerals to the dietary 
reference intake (DRI) for postmenopausal women. Neither the chronic or normal inflammatory 
group met the recommended dietary allowance (RDA) for folate of 400 mcg, although the 
normal group consumed an average of 10 mcg less than recommendations. The chronic group 
was below the RDA for vitamin B6, 1.5 mg, and both groups did not meet the RDA for 
magnesium of 320 mg. However, both inflammatory groups met the recommended intake for 
vitamin B12, C, and zinc of 2.5 mcg, 75 mg, and 8 mg, respectively.    
 Although animal foods, such as meats, fish, and eggs were included in our table of foods 
containing melatonin, these foods were not counted towards the dietary melatonin consumption 
of each subject. While a single study identified animal foods as containing melatonin that could 
contribute to dietary intake, the samples of meats were raw and the eggs were dried solids.24 
Therefore, we did not have enough data on the degree of melatonin degradation in animal 
products after cooking to enable us to include these foods in our analysis. The dairy products 
included did not make a large contribution to overall dietary melatonin consumption, as milk is a 
poor source of melatonin with only 0.014 ng/g and few subjects in our dataset consumed yogurt 
every day. Nuts and seeds may have made up a small percentage of total melatonin intake since a 
limited number of subjects in the dataset consumed these foods.      
 Interestingly, the chronic inflammatory group obtained a greater percentage of their total 
melatonin intake from fruits and vegetables and a smaller percentage from grains than did the 
normal inflammatory group. Although we had expected that individuals with less inflammation 
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would consume more dietary melatonin from fruits and vegetables, there are some plausible 
explanations for this unintuitive outcome. First, there were only two days of 24-hour dietary 
recall data available from the NHANES datasets; the available data simply provide a snapshot of 
each subject’s dietary intake for a very brief window of time. This dietary information may not 
be representative of each inflammatory group’s usual dietary intake, which could have accounted 
for the differences in melatonin consumption from produce. Response bias may have also 
influenced these results. Since the two 24-hour dietary recalls were spaced only 3-10 days apart, 
it is possible that subjects in the chronic inflammatory group could have altered their dietary 
intake after completing the first dietary recall to make their dietary choices appear healthier. 
Finally, the individuals with chronic inflammation may also have had a greater prevalence of 
conditions under the active care of a physician. These individuals may therefore have been 
encouraged by healthcare professionals or influenced by other sources to consume a healthier 
diet to reduce the risks associated with disease.     
 
Study Limitations and Strengths 
 There are a number of limitations to this study that should be considered. First, the cross-
sectional nature of this study did not allow us to determine cause and effect relationships 
between our variables of interest. We were only able to establish whether there are associations 
between dietary melatonin, inflammation, BMD, and sleep, since the NHANES data we used 
was collected at a single point in time. Only two, 24-hour dietary recalls were used in our 
datasets, which may not be representative of each subject’s usual dietary intake. If a different 
method had been used to collect dietary data, such as a food frequency questionnaire, we would 
have been able to assess each subject’s typical intake of certain types of food and obtained a 
! 70 
better estimate of habitual dietary melatonin consumption, and possibly tryptophan intake, from 
each food group. The dietary data we used did not allow us to evaluate whether seasonality plays 
a role melatonin consumption, as the month in which each subject’s 24-hour dietary recalls were 
collected was not included in the data. 
 The melatonin content that we established for each type of food is a best estimate, and could 
vary considerably with plant exposure to different environmental conditions, genotype, degree of 
processing and cooking, animal quality of life, and animal diet. Since we cannot determine the 
exact source and genotype of foods through NHANES data, the melatonin concentration used for 
each food may not be completely accurate. The melatonin content of foods that were identified 
by the studies included in our literature review could also differ depending on the laboratory 
methods that were used to quantify melatonin concentration. Since not all of the studies used the 
same melatonin quantification techniques, there may have been differences in measured 
melatonin content. The amount of dietary tryptophan consumed was not available in the 
NHANES datasets we used. Since tryptophan is the starting substrate for endogenous melatonin 
synthesis, it would have been useful to assess the relationships between tryptophan consumption, 
inflammation, BMD, and sleep in our study sample. If subjects with greater tryptophan 
consumption had less inflammation, higher BMD, and adequate sleep compared to those with a 
low tryptophan intake, it is possible that some of this dietary tryptophan could have been used 
for endogenous melatonin production, therefore increasing the amount of melatonin available to 
mitigate inflammation, oxidative stress, and increase BMD.   
 We used CRP as the primary marker of inflammation to separate the postmenopausal women 
into the chronic and normal inflammatory groups. However, CRP may be elevated due to minor 
infections or a low-grade, acute activation of the immune system, rather than from long-term, 
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chronic inflammation. Therefore, using CRP could have classified individuals as being 
chronically inflamed when their CRP level was elevated for a different reason. Since the three 
NHANES datasets used for this study did not include physical activity questionnaires with 
identical questions, it was difficult for us to evaluate the relationship between type and degree of 
physical activity on inflammation, BMD, sleep, and consumption of dietary melatonin. The 
physical activity questionnaires did not distinguish between weight-bearing activities and non-
weight bearing activities, each of which would have differing effects on BMD. Further, the 
frequency and amount of physical activity were not listed as continuous variables, which would 
have made it difficult for us to include physical activity in our statistical analyses that require 
continuous variables. We did not include all possible covariates in our analysis, such as age, 
smoking, alcohol consumption, socioeconomic status, or race and ethnicity, as we already had a 
large number of variables in our dataset that made our analysis complex. Multivariate analysis 
requires that the number of observations exceed the number of variables included in a given 
model. Although our sample sizes were reasonably larger, we could not include additional 
variables without violating the basic premise of the multivariate analysis. However, excluding 
these covariates prevented us from assessing whether they had any influence on our outcome 
variables of interest. It also prevented us from evaluating whether there are trends in 
inflammation, melatonin consumption, BMD, or sleep according to socioeconomic status or race 
and ethnicity. To include these covariates in the analysis, we would have required many 
additional years of data to significantly increase our sample sizes.  
 In spite of its limitations, there are a number of strengths to this study. NHANES data is 
accurate, reliable, and samples a group of individuals who are representative of the general 
United States population. This means that our sample is likely representative of the average 
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postmenopausal woman in the United States. We also had a large sample size of postmenopausal 
women, with 55 individuals in each inflammatory group, which provided us with enough power 
to detect statistically significant differences between each group. Furthermore, it was beneficial 
that we separated individuals with chronic inflammation from those with a normal level of 
inflammation. This not only allowed us to look for differences in mean values between 
individuals of different inflammatory states, but also enabled us to assess the unique ways in 
which our variables of interest were related to one another within each inflammatory group. 
Separating the study participants in this way also allowed us to evaluate the most important 
variables that accounted for the differences between each group. While 24-hour dietary recalls 
may not represent usual dietary intake, this method of dietary data collection has advantages. 
This method is objective and does not require a large amount of time to complete, therefore 
reducing participant burden. The 24-hour recall provides detailed information of an individual’s 
dietary intake, such as food brands, serving sizes, and preparation methods, and multiple pass 
methods can help identify missing or commonly underreported foods.    
 This study was novel in that we assessed the relationships between key variables of interest, 
including inflammation, BMD, and sleep in a relatively unexplored area of dietary melatonin. 
We collected literature on research that has already been done in each of these areas, and created 
a study that integrated each of these variables, allowing us to begin to identify possible 
relationships of biological significance. We also conducted a thorough literature review to 
identify as many foods as possible that contain melatonin. By averaging multiple reported 
melatonin concentrations for each food, and only including cooked foods with evidence of 
melatonin remaining after heat exposure, our melatonin concentrations used were a conservative 
estimate. This ensured that we did not overestimate the potential contribution of each food to the 
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total dietary melatonin intake, and that we did not assume that cooked produce and meats contain 
melatonin when there is insufficient evidence to support this. This study is also strong in that we 
considered the biological impact of dietary-derived melatonin, rather than supplemental 
melatonin. Since melatonin is an antioxidant and anti-inflammatory compound found in whole 
foods, it is important to assess the impact of consuming low-grade doses of melatonin from 
whole foods over a long period of time, rather than pharmacological doses that can only be 
obtained from supplements.  
 
Conclusions and Future Directions 
 To the best of our knowledge, this is the first study to examine the relationships between 
melatonin derived from whole foods and inflammation, BMD, and sleep in postmenopausal 
women. While recent studies have begun to assess whether dietary melatonin consumption 
increases plasma levels of melatonin metabolites, we successfully applied available data on food 
melatonin concentrations to the 24-hour dietary recalls of a sample of postmenopausal women 
representative of the general US population. Our results support our proposal that dietary-derived 
melatonin may have an impact on inflammation, BMD, and sleep, as individuals with normal 
levels of inflammation had significantly greater BMD and melatonin consumption compared to 
the chronic inflammatory group. While we did not see a direct association between melatonin 
consumption and inflammation, BMD, and sleep, our results suggest that melatonin from whole 
foods may indirectly affect these outcomes and may work with other nutrients to reduce 
inflammatory and oxidative processes that could negatively affect BMD and circadian rhythm.  
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 Therefore, our findings support the need for further investigation to understand the exact 
mechanisms by which dietary melatonin is absorbed, assimilated, and the biological pathways in 
which it is involved in promoting BMD and reducing inflammation. Our study supports the need 
to identify additional foods that contain melatonin, and to obtain a better understanding of how 
heat, cooking, and processing affect the melatonin concentration of foods. This study also 
illustrates that dietary-derived melatonin may be part of a healthy dietary pattern for improving 
BMD and reducing the risk for osteopenia and osteoporosis in postmenopausal women. While 
previous studies have found improvements in BMD after high-dose melatonin supplementation, 
our study supports the need for more investigation into the effects of long-term, low-dose 
consumption of melatonin from whole foods.    
 Future research should incorporate covariates into the analysis, including age, socioeconomic 
status, education level, smoking, and alcohol consumption to understand whether they reveal 
patterns in melatonin consumption, BMD, inflammation, and sleep. Examining melatonin 
consumption and relationships with our variables of interest among different ethnic groups 
would make it possible to identify whether individuals with certain genotypes have an increased 
or reduced capacity to make endogenous melatonin or to process exogenous sources of 
melatonin. Including tryptophan in the dataset would be beneficial for evaluating endogenous 
synthesis of melatonin, since this is the starting substrate for melatonin production. It would also 
be important to evaluate the effects of estrogen replacement therapy on the actions of melatonin 
in postmenopausal women, as studies have illustrated that melatonin and estrogen may work 
synergistically to improve BMD. Further, using a dietary data collection method that provides 
information on usual dietary intake over time would be a more accurate way of estimating usual 
intake of dietary melatonin. Finally, dietary data collection should consider the role of 
! 75 
seasonality and geography in melatonin consumption, as fruits and vegetables that are rich in 
melatonin may only be available during certain times of the year, melatonin-rich foods may be 
grown in specific locations, and environmental exposures in different climate regions could 
change the food melatonin content.           
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Appendix A 
Variables Included in Initial Factor Analysis 
Dietary: Melatonin, Calories, Protein, Folate, Vitamin B6, Vitamin B12, Vitamin C, 
Magnesium, Zinc  
Bone: Femur BMD 
Biochemical: C-reactive Protein, HDL Cholesterol (log10-transformed), Alkaline Phosphatase 
(1/x-transformed) 
Lifestyle: Hours of Sleep, Sedentary Time 
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Appendix B 
Factor Analysis 
a)!Descriptive Statistics 
 
Descriptive+Statistics!
 ! Mean! Std.!Deviationa! Analysis!Na! Missing!N!
C5Reactive!Protein! 1.92! 1.99!! 110.00! 0.00!
Alkaline!Phosphatase!(1/x!normal)! 0.01! 0.01! 110.00! 4.00!
HDL!ln5normalized! 4.01! 0.25! 110.00! 3.00!
Femur!BMD! 0.87! 0.17! 110.00! 0.00!
Melatonin!(ln5normal)! 5.59! 1.91! 110.00! 1.00!
B12! 4.92! 4.17! 110.00! 0.00!
Folate! 345.19! 135.27! 110.00! 0.00!
B6! 1.65! 0.68! 110.00! 0.00!
Energy! 1673.20! 555.78! 110.00! 1.00!
Protein! 65.07! 21.73! 110.00! 1.00!
Magnesium! 255.02! 92.47! 110.00! 0.00!
Zinc! 9.98! 6.59! 110.00! 0.00!
Vitamin!C!ln! 4.09! 0.83! 110.00! 0.00!
Sleep!(hours)! 7.04! 1.61! 110.00! 0.00!
Sedentary!Time! 320.26! 126.07! 110.00! 33.00!
a.!For!each!variable,!missing!values!are!replaced!with!the!variable!mean.!
 !
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b)!Total Variance Explained 
Total+Variance+Explained!
Component!
Initial!Eigenvalues! Extraction!Sums!of!Squared!Loadings!
Total! %!of!Variance! Cumulative!%! Total! %!of!Variance! Cumulative!%!
1! 4.182! 27.878! 27.878! 4.182! 27.878! 27.878!
2! 1.607! 10.711! 38.589! 1.607! 10.711! 38.589!
3! 1.398! 9.319! 47.908! 1.398! 9.319! 47.908!
4! 1.211! 8.075! 55.984! 1.211! 8.075! 55.984!
5! 1.085! 7.232! 63.216!    
6! .927! 6.181! 69.397!    
7! .874! 5.824! 75.221!    
8! .795! 5.297! 80.518!    
9! .723! 4.818! 85.336!    
10! .637! 4.249! 89.585!    
11! .500! 3.332! 92.917!    
12! .346! 2.309! 95.226!    
13! .318! 2.123! 97.350!    
14! .232! 1.547! 98.896!    
15! .166! 1.104! 100.000!    
Extraction!Method:!Principal!Component!Analysis.!
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c)!Scree Plot 
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d)!Component Matrix 
Component+Matrixa!
 
Component!
1! 2! 3! 4!
C5Reactive!Protein! 5.183! 5.337! .656! 5.120!
Alkaline!Phosphatase!(1/x!normal)! .223! .468! 5.090! 5.153!
HDL!ln5normalized! .326! .479! 5.269! 5.393!
Femur!BMD! .208! 5.028! 5.509! .509!
Melatonin!(ln5normal)! .369! .393! .175! .151!
B12! .349! 5.252! 5.304! 5.418!
Folate! .777! .201! .037! .062!
B6! .831! .031! .227! .094!
Energy! .696! 5.380! 5.057! .011!
Protein! .788! 5.364! 5.003! .029!
Magnesium! .871! .133! .088! .135!
Zinc! .557! 5.529! 5.198! 5.185!
Vitamin!C!ln! .431! .429! .329! .055!
Sleep!(hours)! .171! 5.113! .543! 5.057!
Sedentary!Time! 5.086! 5.111! .008! .700!
Extraction!Method:!Principal!Component!Analysis.!
a.!4!components!extracted.!
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Appendix C 
Discriminant Function Analysis  
a)!Tests of Equality of Group Means 
Tests+of+Equality+of+Group+Means!
 Wilks'!Lambda! F! df1! df2! Sig.!
HDL!ln5normalized! .946! 5.683! 1! 99! .019!
Alkaline!Phosphatase!(1/x!
normal)!
.971! 2.984! 1! 99! .087!
Melatonin!(ln5normal)! .958! 4.303! 1! 99! .041!
Vitamin!C!ln! .988! 1.224! 1! 99! .271!
Femur!BMD! .971! 2.986! 1! 99! .087!
Folate! .886! 12.692! 1! 99! .001!
Magnesium! .908! 10.078! 1! 99! .002!
B6! .968! 3.257! 1! 99! .074!
Energy! .992! .846! 1! 99! .360!
Zinc! .999! .086! 1! 99! .770!
B12! .972! 2.865! 1! 99! .094!
Protein! .994! .596! 1! 99! .442!
Sleep!(hours)! 1.000! .001! 1! 99! .980!
 
b)!Test for Multivariate Normality 
Test+Results!
Box's!M! 1.059!
F! Approx.! 1.048!
df1! 1!
df2! 29012.954!
Sig.! .306!
Tests!null!hypothesis!of!equal!population!covariance!
matrices.!
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c)!Variables Entered/Removed 
Variables+Entered/Removeda,b,c,d!
Step! Entered!
Wilks'!Lambda!
Statistic! df1! df2! df3!
Exact!F!
Statistic! df1! df2! Sig.!
1! Folate! .886! 1! 1! 99.000! 12.692! 1! 99.000! .001!
At!each!step,!the!variable!that!minimizes!the!overall!Wilks'!Lambda!is!entered.!
a.!Maximum!number!of!steps!is!26.!
b.!Minimum!partial!F!to!enter!is!3.84.!
c.!Maximum!partial!F!to!remove!is!2.71.!
d.!F!level,!tolerance,!or!VIN!insufficient!for!further!computation.!
 
 
d)!Wilks’ Lambda Test of Function(s) 
Wilks'+Lambda!
Test!of!Function(s)! Wilks'!Lambda! Chi5square! df! Sig.!
1! .886! 11.881! 1! .001!
 
 
e)!Standardized Canonical Discriminant Function Coefficients 
Standardized+Canonical+Discriminant+Function+Coefficients!
 
Function!
1!
Folate! 1.000!
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f)! Structure Matrix 
Structure+Matrix!
 
Function!
1!
Folate! 1.000!
B6a! .640!
Magnesiuma! .606!
Energya! .493!
Proteina! .486!
Melatonin!(ln5normal)a! .321!
Vitamin!C!lna! .316!
Zinca! .280!
Alkaline!Phosphatase!(1/x!normal)a! .163!
B12a! .150!
HDL!ln5normalizeda! .123!
Sleep!(hours)a! .105!
Femur!BMDa! .052!
Pooled!within5groups!correlations!between!discriminating!variables!and!standardized!canonical!
discriminant!functions!!
!Variables!ordered!by!absolute!size!of!correlation!within!function.!
a.!This!variable!not!used!in!the!analysis.!
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g) Canonical Discriminant Function Histograms 
 
 
 
 
Group 1 = Low inflammatory  
Group 2 = Chronic inflammatory 
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Appendix D 
Means Tests 
a)! CRP 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable C_Reactive_Protein 
Classified by Variable Group 
Group N Mean 
Normal 55 0.415818 
Chronic 55 3.426909 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 249.333383 249.333383 146.9541 <.0001 
Within 108 183.240913 1.696675     
Average scores were used for ties. 
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!
!
Wilcoxon Scores (Rank Sums) for Variable C_Reactive_Protein 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 55 1540.0 3052.50 167.258624 28.0 
Chronic 55 4565.0 3052.50 167.258624 83.0 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 1540.0000 
    
Normal Approximation   
Z -9.0399 
One-Sided Pr < Z <.0001 
Two-Sided Pr > |Z| <.0001 
    
t Approximation   
One-Sided Pr < Z <.0001 
Two-Sided Pr > |Z| <.0001 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 81.7737 
DF 1 
Pr > Chi-Square <.0001 
!
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!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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b)! Alkaline Phosphatase  
 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Alkaline_Phosphatase__1_x_normal 
Classified by Variable Group 
Group N Mean 
Normal 51 0.013952 
Chronic 55 0.012972 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 0.000025 0.000025416 2.8956 0.0918 
Within 104 0.000913 8.777366E-6     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Alkaline_Phosphatase__1_x_normal 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 51 3012.0 2728.50 158.072546 59.058824 
Chronic 55 2659.0 2942.50 158.072546 48.345455 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 3012.0000 
    
Normal Approximation   
Z 1.7903 
One-Sided Pr > Z 0.0367 
Two-Sided Pr > |Z| 0.0734 
    
t Approximation   
One-Sided Pr > Z 0.0381 
Two-Sided Pr > |Z| 0.0763 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 3.2166 
DF 1 
Pr > Chi-Square 0.0729 
!
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!
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c)! HDL Cholesterol 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable HDL_ln_normalized 
Classified by Variable Group 
Group N Mean 
Normal 53 4.068723 
Chronic 54 3.955954 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 0.340147 0.340147 5.5172 0.0207 
Within 105 6.473458 0.061652     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable HDL_ln_normalized 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 53 3198.0 2862.0 160.434413 60.339623 
Chronic 54 2580.0 2916.0 160.434413 47.777778 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 3198.0000 
    
Normal Approximation   
Z 2.0912 
One-Sided Pr > Z 0.0183 
Two-Sided Pr > |Z| 0.0365 
    
t Approximation   
One-Sided Pr > Z 0.0195 
Two-Sided Pr > |Z| 0.0389 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 4.3862 
DF 1 
Pr > Chi-Square 0.0362 
!
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d)!  Femur BMD 
The!TTEST!Procedure!
!
Variable:!Femur_BMD!
Group N Mean Std Dev Std Err Minimum Maximum 
Chronic 55 0.8382 0.1599 0.0216 0.4700 1.2600 
Normal 55 0.9011 0.1707 0.0230 0.6060 1.4030 
Diff (1-2)   -0.0629 0.1654 0.0315     
!
Group Method Mean 95% CL Mean Std Dev 95% CL Std Dev 
Chronic   0.8382 0.7950 0.8814 0.1599 0.1346 0.1970 
Normal   0.9011 0.8550 0.9473 0.1707 0.1437 0.2103 
Diff (1-2) Pooled -0.0629 -0.1255 -0.00043 0.1654 0.1460 0.1908 
Diff (1-2) Satterthwaite -0.0629 -0.1255 -0.00043       
!
Method Variances DF t Value Pr > |t| 
Pooled Equal 108 -2.00 0.0485 
Satterthwaite Unequal 107.54 -2.00 0.0485 
!
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 54 54 1.14 0.6331 
!
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!
!
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e)!  Melatonin 
 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Melatonin__ln_normal_ 
Classified by Variable Group 
Group N Mean 
Normal 54 5.983812 
Chronic 55 5.209435 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 16.339374 16.339374 4.6008 0.0342 
Within 107 380.002233 3.551423     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Melatonin__ln_normal_ 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 54 3312.0 2970.0 164.998471 61.333333 
Chronic 55 2683.0 3025.0 164.998471 48.781818 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 3312.0000 
    
Normal Approximation   
Z 2.0697 
One-Sided Pr > Z 0.0192 
Two-Sided Pr > |Z| 0.0385 
    
t Approximation   
One-Sided Pr > Z 0.0204 
Two-Sided Pr > |Z| 0.0409 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 4.2963 
DF 1 
Pr > Chi-Square 0.0382 
!
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f)! Calories 
!
!
The!TTEST!Procedure!
!!
Variable:!Energy!
Group N Mean Std Dev Std Err Minimum Maximum 
Chronic 54 1625.6 563.5 76.6867 623.5 3098.5 
Normal 54 1690.2 513.6 69.8895 837.5 3015.5 
Diff (1-2)   -64.6204 539.1 103.8     
!
Group Method Mean 95% CL Mean Std Dev 95% CL Std Dev 
Chronic   1625.6 1471.8 1779.4 563.5 473.7 695.7 
Normal   1690.2 1550.1 1830.4 513.6 431.7 634.0 
Diff (1-2) Pooled -64.6204 -270.3 141.1 539.1 475.3 622.9 
Diff (1-2) Satterthwaite -64.6204 -270.3 141.1       
!
Method Variances DF t Value Pr > |t| 
Pooled Equal 106 -0.62 0.5347 
Satterthwaite Unequal 105.1 -0.62 0.5348 
!
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 53 53 1.20 0.5016 
!
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!
!
!
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g)! Protein  
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Protein 
Classified by Variable Group 
Group N Mean 
Normal 54 66.828056 
Chronic 55 63.342000 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 331.130023 331.130023 0.6927 0.4071 
Within 107 51148.020751 478.018886     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Protein 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 54 3136.50 2970.0 164.999618 58.083333 
Chronic 55 2858.50 3025.0 164.999618 51.972727 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 3136.5000 
    
Normal Approximation   
Z 1.0061 
One-Sided Pr > Z 0.1572 
Two-Sided Pr > |Z| 0.3144 
    
t Approximation   
One-Sided Pr > Z 0.1583 
Two-Sided Pr > |Z| 0.3166 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 1.0183 
DF 1 
Pr > Chi-Square 0.3129 
!
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!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
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h)! Folate 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Folate 
Classified by Variable Group 
Group N Mean 
Normal 55 390.300000 
Chronic 54 293.379630 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 255952.915894 255952.9159 16.7283 <.0001 
Within 107 1637164.267593 15300.6006     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Folate 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 55 3690.50 3025.0 164.998853 67.100000 
Chronic 54 2304.50 2970.0 164.998853 42.675926 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 2304.5000 
    
Normal Approximation   
Z -4.0303 
One-Sided Pr < Z <.0001 
Two-Sided Pr > |Z| <.0001 
    
t Approximation   
One-Sided Pr < Z <.0001 
Two-Sided Pr > |Z| 0.0001 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 16.2680 
DF 1 
Pr > Chi-Square <.0001 
!
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i)! Vitamin B12 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable B12 
Classified by Variable Group 
Group N Mean 
Normal 52 4.501827 
Chronic 51 4.033137 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 5.655969 5.655969 1.5159 0.2211 
Within 101 376.838049 3.731070     
Average scores were used for ties. 
!
!
! 108 
Wilcoxon Scores (Rank Sums) for Variable B12 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 52 2912.50 2704.0 151.602668 56.009615 
Chronic 51 2443.50 2652.0 151.602668 47.911765 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 2443.5000 
    
Normal Approximation   
Z -1.3720 
One-Sided Pr < Z 0.0850 
Two-Sided Pr > |Z| 0.1701 
    
t Approximation   
One-Sided Pr < Z 0.0865 
Two-Sided Pr > |Z| 0.1731 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 1.8915 
DF 1 
Pr > Chi-Square 0.1690 
!
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!
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j)! Vitamin B6 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable B6 
Classified by Variable Group 
Group N Mean 
Normal 54 1.767620 
Chronic 51 1.397059 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 3.601599 3.601599 12.8673 0.0005 
Within 103 28.830029 0.279903     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable B6 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 54 3425.0 2862.0 155.967917 63.425926 
Chronic 51 2140.0 2703.0 155.967917 41.960784 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 2140.0000 
    
Normal Approximation   
Z -3.6065 
One-Sided Pr < Z 0.0002 
Two-Sided Pr > |Z| 0.0003 
    
t Approximation   
One-Sided Pr < Z 0.0002 
Two-Sided Pr > |Z| 0.0005 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 13.0301 
DF 1 
Pr > Chi-Square 0.0003 
!
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k)! Vitamin C 
The!TTEST!Procedure!
!!
Variable:!Vitamin_C_ln!
Group N Mean Std Dev Std Err Minimum Maximum 
Chronic 55 3.9778 0.8972 0.1210 1.8641 5.8003 
Normal 55 4.1942 0.7480 0.1009 2.5533 5.5744 
Diff (1-2)   -0.2164 0.8260 0.1575     
!
Group Method Mean 95% CL Mean Std Dev 95% CL Std Dev 
Chronic   3.9778 3.7352 4.2203 0.8972 0.7553 1.1052 
Normal   4.1942 3.9919 4.3964 0.7480 0.6297 0.9214 
Diff (1-2) Pooled -0.2164 -0.5286 0.0958 0.8260 0.7290 0.9530 
Diff (1-2) Satterthwaite -0.2164 -0.5287 0.0960       
!
Method Variances DF t Value Pr > |t| 
Pooled Equal 108 -1.37 0.1724 
Satterthwaite Unequal 104.61 -1.37 0.1725 
!
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 54 54 1.44 0.1845 
!
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l)! Magnesium 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Magnesium_ln 
Classified by Variable Group 
Group N Mean 
Normal 55 5.599662 
Chronic 54 5.377465 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 1.345255 1.345255 12.8381 0.0005 
Within 107 11.212155 0.104786     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Magnesium_ln 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 55 3591.50 3025.0 164.996177 65.300000 
Chronic 54 2403.50 2970.0 164.996177 44.509259 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 2403.5000 
    
Normal Approximation   
Z -3.4304 
One-Sided Pr < Z 0.0003 
Two-Sided Pr > |Z| 0.0006 
    
t Approximation   
One-Sided Pr < Z 0.0004 
Two-Sided Pr > |Z| 0.0009 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 11.7883 
DF 1 
Pr > Chi-Square 0.0006 
!
! 117 
!
 
 
 
 
 
 
 
 
 
 
 
 
 
! 118 
m)!Zinc 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Zinc_ln 
Classified by Variable Group 
Group N Mean 
Normal 55 2.224702 
Chronic 54 2.094350 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 0.462983 0.462983 2.5254 0.1150 
Within 107 19.616405 0.183331     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Zinc_ln 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 55 3274.50 3025.0 164.998089 59.536364 
Chronic 54 2720.50 2970.0 164.998089 50.379630 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 2720.5000 
    
Normal Approximation   
Z -1.5091 
One-Sided Pr < Z 0.0656 
Two-Sided Pr > |Z| 0.1313 
    
t Approximation   
One-Sided Pr < Z 0.0671 
Two-Sided Pr > |Z| 0.1342 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 2.2866 
DF 1 
Pr > Chi-Square 0.1305 
!
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n)! Sedentary Time 
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Sedentary_Time 
Classified by Variable Group 
Group N Mean 
Normal 36 330.000000 
Chronic 41 311.707317 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 6414.317390 6414.31739 0.2787 0.5991 
Within 75 1725980.487805 23013.07317     
Average scores were used for ties. 
!
!
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Wilcoxon Scores (Rank Sums) for Variable Sedentary_Time 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 36 1429.0 1404.0 97.040272 39.694444 
Chronic 41 1574.0 1599.0 97.040272 38.390244 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 1429.0000 
    
Normal Approximation   
Z 0.2525 
One-Sided Pr > Z 0.4003 
Two-Sided Pr > |Z| 0.8007 
    
t Approximation   
One-Sided Pr > Z 0.4007 
Two-Sided Pr > |Z| 0.8014 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 0.0664 
DF 1 
Pr > Chi-Square 0.7967 
!
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o)! Hours of Sleep 
!
The!NPAR1WAY!Procedure!
Analysis of Variance for Variable Sleep__hours_ 
Classified by Variable Group 
Group N Mean 
Normal 54 6.944444 
Chronic 53 7.037736 
!
Source DF Sum of Squares Mean Square F Value Pr > F 
Among 1 0.232793 0.232793 0.1171 0.7329 
Within 105 208.757862 1.988170     
Average scores were used for ties. 
!
!
!
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Wilcoxon Scores (Rank Sums) for Variable Sleep__hours_ 
Classified by Variable Group 
Group N Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
Normal 54 2925.0 2916.0 156.474297 54.166667 
Chronic 53 2853.0 2862.0 156.474297 53.830189 
Average scores were used for ties. 
!
Wilcoxon Two-Sample Test 
Statistic 2853.0000 
    
Normal Approximation   
Z -0.0543 
One-Sided Pr < Z 0.4783 
Two-Sided Pr > |Z| 0.9567 
    
t Approximation   
One-Sided Pr < Z 0.4784 
Two-Sided Pr > |Z| 0.9568 
Z includes a continuity correction of 0.5. 
!
Kruskal-Wallis Test 
Chi-Square 0.0033 
DF 1 
Pr > Chi-Square 0.9541 
!
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Appendix E 
Simple Linear Regression 
a)!  CRP and Dietary Melatonin 
Simple linear regression between dietary melatonin and CRP in low and chronic 
inflammatory individuals (n = 109). Normal group b = 0.48, R2 = 0.02, F(1, 52) = 0.88, p = 
0.35 and chronic group b = 0.07, R2 = 0.003, F(1, 53) = 0.18, p = 0.67. 
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b)! CRP and Caloric Intake  
Simple linear regression between caloric intake and CRP in low and chronic inflammatory 
individuals (n = 108). Normal group b = 15.69, R2 = 0.0002, F(1, 52) = 0.009, p = 0.92 
and chronic group b = 13.97, R2 = 0.002, F(1, 52) = 0.10, p = 0.75. 
c)! CRP and Protein 
Simple linear regression between dietary protein and CRP in low and chronic 
inflammatory individuals (n = 109). Normal group b = 1.39, R2 = 0.001, F(1, 52) = 0.06, p 
= 0.81 and chronic group b = 1.42, R2 = 0.01, F(1, 53) = 0.55, p = 0.46. 
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d)! CRP and Folate 
Simple linear regression between folate and CRP in low and chronic inflammatory 
individuals (n = 109). Normal group b = 16.93, R2 = 0.004, F(1, 53) = 0.20, p = 0.65 and 
chronic group b = 3.98, R2 = 0.003, F(1, 52) = 0.16, p = 0.69.!
 
e)! CRP and Vitamin B12 
Simple linear regression between vitamin B12 and CRP in low and chronic inflammatory 
individuals (n = 103). Normal group b = 0.16, R2 = 0.002, F(1, 50) = 0.08, p = 0.78 and 
chronic group b = 0.20, R2 = 0.03, F(1, 49) = 1.6, p = 0.21. 
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f)! CRP and Vitamin B6 
Simple linear regression between vitamin B6 and CRP in low and chronic inflammatory 
individuals (n = 105). Normal group b = 0.12, R2 = 0.008, F(1, 52) = 0.43, p = 0.51 and 
chronic group b = -0.02, R2 = 0.003, F(1, 49) = 0.17, p = 0.68.  
!
g)! CRP and Vitamin C 
Simple linear regression between vitamin C and CRP in low and chronic inflammatory 
individuals (n = 110). Normal group b = 0.04, R2 = 0.0006, F(1, 53) = 0.03, p = 0.86 and 
chronic group   b = 0.13, R2 = 0.07, F(1, 53) = 3.85, p = 0.055.!
Normal
y!=!0.1057x!+!1.7235
R²!=!0.0082
Chronic
y!=!L0.0216x!+!1.4671
R²!=!0.0034
0
0.5
1
1.5
2
2.5
3
3.5
0 1 2 3 4 5 6 7 8 9
Vi
ta
m
in
)B
6)
(m
g)
C*reactive)Protein)(mg/dL)
Normal
y!=!0.0435x!+!4.1761
R²!=!0.0006
Chronic
y!=!0.1304x!+!3.5308
R²!=!0.0678
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7 8 9 10
Vi
ta
m
in
)C
)ln
*n
or
m
al
ize
d)
(m
g)
C*reactive)Protein)(mg/dL)
! 131 
h)! CRP and Magnesium 
Simple linear regression between magnesium and CRP in low and chronic inflammatory 
individuals (n = 109). Normal group b = 0.04, R2 = 0.003, F(1, 53) = 0.15, p = 0.70 and 
chronic group b = 0.03, R2 = 0.03, F(1, 52) = 1.80, p = 0.19. 
!
i)! CRP and Zinc 
Simple linear regression between zinc and CRP in low and chronic inflammatory 
individuals (n = 109). Normal group b = 0.12, R2 = 0.02, F(1, 53) = 0.90, p = 0.35 and 
chronic group b = 0.004, R2 = 0.0003, F(1, 52) = 0.01, p = 0.90.!
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j)! CRP and Sleep 
Simple linear regression between hours of sleep and CRP in low and chronic 
inflammatory individuals (n = 107). Normal group b = 0.53, R2 = 0.04, F(1, 52) = 2.06, p 
= 0.16 and chronic group b = 0.24, R2 = 0.08, F(1, 51) = 4.20, p = 0.045. 
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Appendix F 
Multivariate Linear Regression  
a)!Descriptive Statistics – Chronic Inflammatory Group 
Simple Statistics 
Variable N Mean Std Dev Sum Minimum Maximum 
C_Reactive_Protein 55 3.43 1.79 188.48 2.00 9.49 
Alkaline_Phosphatase__1_x
_normal 
55 0.01 0.00 0.71 0.01 0.02 
HDL_ln_normalized 54 3.96 0.28 213.62 3.29 4.49 
Femur_BMD 55 0.84 0.16 46.10 0.47 1.26 
Melatonin__ln_normal_ 55 5.21 2.09 286.52 0.00 8.78 
Energy 54 1626.00 563.53 87784.00 623.50 3099.00 
Protein 55 63.34 25.27 3484.00 17.22 129.43 
Folate 54 293.38 129.17 15843.00 97.50 622.50 
B12 51 4.03 2.09 205.69 1.02 9.33 
B6 51 1.39 0.55 71.25 0.49 2.98 
Vitamin_C_ln 55 3.98 0.89 218.78 1.86 5.80 
Magnesium_ln 54 5.38 0.34 290.38 4.65 6.15 
Zinc_ln 54 2.09 0.46 113.09 0.85 3.09 
Sedentary_Time 41 311.71 147.71 12780.00 60.00 600.00 
Sleep__hours_ 53 7.04 1.60 373.00 4.00 11.00 
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b)!Descriptive Statistics – Normal Inflammatory Group 
Simple Statistics 
Variable N Mean Std Dev Sum Minimum Maximum 
C_Reactive_Protein 55 0.42 0.43 22.87 0.01 1.72 
Alkaline_Phosphatase__1_x
_normal 
51 0.01 0.00 0.71 0.01 0.02 
HDL_ln_normalized 53 4.07 0.20 215.64 3.58 4.48 
Femur_BMD 55 0.90 0.17 49.56 0.61 1.40 
Melatonin__ln_normal_ 54 5.98 1.64 323.13 0.00 8.88 
Energy 54 1690.00 513.58 91273.00 837.50 3016.00 
Protein 54 66.83 17.73 3609.00 33.06 113.56 
Folate 55 390.30 118.07 21467.00 182.00 684.00 
B12 52 4.50 1.76 234.09 1.88 8.74 
B6 54 1.77 0.51 95.45 0.71 2.71 
Vitamin_C_ln 55 4.19 0.75 230.68 2.55 5.57 
Magnesium_ln 55 5.59 0.31 307.98 5.03 6.43 
Zinc_ln 55 2.22 0.39 122.36 1.38 3.22 
Sedentary_Time 36 330.00 156.13 11880.00 120.00 720.00 
Sleep__hours_ 54 6.94 1.19 375.00 4.00 9.00 
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Appendix G 
Path Analysis  
a)! Regression Weights – Chronic Inflammatory Group 
Regression Weights: (Group number 1 - Default model) 
! ! ! Estimate! S.E.! C.R.! P!
Melatoninlnnormal! <LLL! Magnesiumln! 3.51! .83! 4.24! ***!
Protein! <LLL! Energy! .02! .00! 4.83! ***!
Protein! <LLL! Magnesiumln! L11.96! 6.87! L1.74! .08!
Protein! <LLL! Zincln! 12.29! 5.22! 2.36! .02!
Protein! <LLL! B12! 3.26! .98! 3.31! ***!
Protein! <LLL! B6! 11.22! 3.24! 3.46! ***!
Melatoninlnnormal! <LLL! Zincln! 4.81! 1.04! 4.62! ***!
Protein! <LLL! Folate! L.05! .014! L3.74! ***!
CReactiveProtein! <LLL! Sleephours! .28! .13! 2.24! .03!
CReactiveProtein! <LLL! AlkalinePhosphatase1xnormal! 39.31! 60.63! .65! .52!
CReactiveProtein! <LLL! Folate! L.01! .00! L4.03! ***!
FemurBMD! <LLL! CReactiveProtein! L.02! .01! L2.27! .02!
Melatoninlnnormal! <LLL! Protein! L.13! .03! L4.02! ***!
Protein! <LLL! Melatoninlnnormal! 6.25! 1.72! 3.63! ***!
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b)! Model: Melatonin = Folate x Protein x Magnesium x Zinc 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! Zincln,!
Magnesiumln,!
Folate,!Proteinb!
.! Enter!
a.!Dependent!Variable:!Melatoninlnnormal!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .530a! .281! .209! 1.83612569000
0000!
a.!Predictors:!(Constant),!Zincln,!Magnesiumln,!Folate,!Protein!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 52.659! 4! 13.165! 3.905! .009b!
Residual! 134.854! 40! 3.371!   
Total! 187.514! 44!    
a.!Dependent!Variable:!Melatoninlnnormal!
b.!Predictors:!(Constant),!Zincln,!Magnesiumln,!Folate,!Protein!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 513.090! 6.106!  52.144! .038!
Folate! 5.002! .004! 5.114! 5.566! .575!
Protein! 5.006! .021! 5.060! 5.282! .779!
Magnesiumln! 2.892! 1.283! .403! 2.254! .030!
Zincln! 1.753! 1.399! .316! 1.253! .217!
a.!Dependent!Variable:!Melatoninlnnormal!
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c)! Model: CRP = Femur BMD x Alkaline Phosphatase 
  
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! FemurBMD,!
AlkalinePhosph
atase1xnormalb!
.! Enter!
a.!Dependent!Variable:!CReactiveProtein!
b.!All!requested!variables!entered.!
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .411a! .169! .130! 1.41945045200
0000!
a.!Predictors:!(Constant),!FemurBMD,!AlkalinePhosphatase1xnormal!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 17.237! 2! 8.618! 4.277! .020b!
Residual! 84.623! 42! 2.015!   
Total! 101.860! 44!    
a.!Dependent!Variable:!CReactiveProtein!
b.!Predictors:!(Constant),!FemurBMD,!AlkalinePhosphatase1xnormal!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 3.771! 1.534!  2.458! .018!
AlkalinePhosphatase1xnorm
al!
135.931! 75.586! .254! 1.798! .079!
FemurBMD! 52.671! 1.264! 5.299! 52.114! .041!
a.!Dependent!Variable:!CReactiveProtein!
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d)! Model: Femur BMD = CRP 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! CReactiveProtei
nb!
.! Enter!
a.!Dependent!Variable:!FemurBMD!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .324a! .105! .084! .162864211000
000!
a.!Predictors:!(Constant),!CReactiveProtein!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! .134! 1! .134! 5.058! .030b!
Residual! 1.141! 43! .027!   
Total! 1.275! 44!    
a.!Dependent!Variable:!FemurBMD!
b.!Predictors:!(Constant),!CReactiveProtein!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! .957! .059!  16.299! .000!
CReactiveProtein! 5.036! .016! 5.324! 52.249! .030!
a.!Dependent!Variable:!FemurBMD!
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e)! Model: Protein = Zinc x Melatonin x Energy x B6 x B12 x Folate x Magnesium 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! Zincln,!
Melatoninlnnorm
al,!Energy,!B6,!
B12,!Folate,!
Magnesiumlnb!
.! Enter!
a.!Dependent!Variable:!Protein!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .825a! .681! .621! 12.8805386100
00000!
a.!Predictors:!(Constant),!Zincln,!Melatoninlnnormal,!Energy,!B6,!B12,!
Folate,!Magnesiumln!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 13098.961! 7! 1871.280! 11.279! .000b!
Residual! 6138.606! 37! 165.908!   
Total! 19237.567! 44!    
a.!Dependent!Variable:!Protein!
b.!Predictors:!(Constant),!Zincln,!Melatoninlnnormal,!Energy,!B6,!B12,!Folate,!Magnesiumln!
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Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 23.783! 55.325!  .430! .670!
Melatoninlnnormal! 1.210! 1.223! .119! .989! .329!
B12! .334! 1.444! .030! .231! .818!
Folate! 5.033! .028! 5.184! 51.181! .245!
B6! 13.571! 6.091! .359! 2.228! .032!
Energy! .013! .005! .313! 2.433! .020!
Magnesiumln! 512.109! 12.241! 5.166! 5.989! .329!
Zincln! 31.100! 9.449! .553! 3.291! .002!
a.!Dependent!Variable:!Protein!
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f)! Model: Sleep = CRP 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! CReactiveProtei
nb!
.! Enter!
a.!Dependent!Variable:!Sleephours!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .253a! .064! .042! 1.570!
a.!Predictors:!(Constant),!CReactiveProtein!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 7.225! 1! 7.225! 2.932! .094b!
Residual! 105.975! 43! 2.465!   
Total! 113.200! 44!    
a.!Dependent!Variable:!Sleephours!
b.!Predictors:!(Constant),!CReactiveProtein!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 6.317! .566!  11.157! .000!
CReactiveProtein! .266! .156! .253! 1.712! .094!
a.!Dependent!Variable:!Sleephours!
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g)! Regression Weights – Normal Inflammatory Groups 
Regression Weights: (Group number 1 - Default model) 
   Estimate S.E. C.R. P 
HDLlnnormalized <--- Magnesiumln .21 .15 1.41 .16 
CReactiveProtein <--- Zincln -.72 .61 -1.19 .24 
FemurBMD <--- Zincln .06 .07 .81 .42 
HDLlnnormalized <--- AlkalinePhosphatase1xnormal -.53 14.62 -.04 .97 
Protein <--- Energy .01 .01 2.77 .01 
Protein <--- Magnesiumln -5.10 6.33 -.81 .42 
Melatoninlnnormal <--- VitaminCln -.09 .37 -.25 .80 
Protein <--- B12 .42 .95 .44 .66 
Protein <--- FemurBMD 17.46 10.53 1.66 .09 
Protein <--- B6 8.66 3.22 2.69 .01 
Protein <--- Zincln 28.49 4.82 5.91 *** 
Protein <--- HDLlnnormalized -2.85 6.45 -.44 .66 
Sleephours <--- CReactiveProtein .27 .15 1.73 .08 
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h)! Model: Melatonin = Vitamin C x B12 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! VitaminCln,!
B12b!
.! Enter!
a.!Dependent!Variable:!Melatoninlnnormal!
b.!All!requested!variables!entered.!
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .411a! .169! .125! 1.66478974100
0000!
a.!Predictors:!(Constant),!VitaminCln,!B12!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 21.419! 2! 10.709! 3.864! .030b!
Residual! 105.318! 38! 2.772!   
Total! 126.737! 40!    
a.!Dependent!Variable:!Melatoninlnnormal!
b.!Predictors:!(Constant),!VitaminCln,!B12!
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 4.892! 1.623!  3.015! .005!
B12! 5.337! .164! 5.304! 52.053! .047!
VitaminCln! .629! .343! .271! 1.835! .074!
a.!Dependent!Variable:!Melatoninlnnormal!
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i)! Model: CRP = Zinc 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! Zinclnb! .! Enter!
a.!Dependent!Variable:!CReactiveProtein!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .405a! .164! .143! .379755872000
000!
a.!Predictors:!(Constant),!Zincln!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 1.107! 1! 1.107! 7.674! .009b!
Residual! 5.624! 39! .144!   
Total! 6.731! 40!    
a.!Dependent!Variable:!CReactiveProtein!
b.!Predictors:!(Constant),!Zincln!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 5.619! .367!  51.690! .099!
Zincln! .459! .166! .405! 2.770! .009!
a.!Dependent!Variable:!CReactiveProtein!
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j)! Model: Alkaline phosphatase = HDL Cholesterol 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! HDLlnnormalize
db!
.! Enter!
a.!Dependent!Variable:!AlkalinePhosphatase1xnormal!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .331a! .110! .087! .002930879190!
a.!Predictors:!(Constant),!HDLlnnormalized!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! .000! 1! .000! 4.809! .034b!
Residual! .000! 39! .000!   
Total! .000! 40!    
a.!Dependent!Variable:!AlkalinePhosphatase1xnormal!
b.!Predictors:!(Constant),!HDLlnnormalized!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 5.007! .009!  5.710! .482!
HDLlnnormalized! .005! .002! .331! 2.193! .034!
a.!Dependent!Variable:!AlkalinePhosphatase1xnormal!
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k)! Model: HDL Cholesterol = Alkaline phosphatase x Energy x Protein x Magnesium x Zinc 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! Zincln,!
AlkalinePhosph
atase1xnormal,!
Magnesiumln,!
Energy,!Proteinb!
.! Enter!
a.!Dependent!Variable:!HDLlnnormalized!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .560a! .313! .215! .178070599000
000!
a.!Predictors:!(Constant),!Zincln,!AlkalinePhosphatase1xnormal,!
Magnesiumln,!Energy,!Protein!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! .507! 5! .101! 3.195! .018b!
Residual! 1.110! 35! .032!   
Total! 1.616! 40!    
a.!Dependent!Variable:!HDLlnnormalized!
b.!Predictors:!(Constant),!Zincln,!AlkalinePhosphatase1xnormal,!Magnesiumln,!Energy,!Protein!
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Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 3.012! .607!  4.960! .000!
AlkalinePhosphatase1xnorm
al!
23.412! 9.587! .357! 2.442! .020!
Energy! .000! .000! .343! 1.755! .088!
Protein! .001! .003! .087! .404! .689!
Magnesiumln! .090! .133! .138! .681! .501!
Zincln! 5.035! .127! 5.064! 5.280! .781!
a.!Dependent!Variable:!HDLlnnormalized!
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l)! Model: Femur BMD = Zinc x Protein 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! Zincln,!Proteinb! .! Enter!
a.!Dependent!Variable:!FemurBMD!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .365a! .133! .087! .158266918000
000!
a.!Predictors:!(Constant),!Zincln,!Protein!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! .146! 2! .073! 2.911! .067b!
Residual! .952! 38! .025!   
Total! 1.098! 40!    
a.!Dependent!Variable:!FemurBMD!
b.!Predictors:!(Constant),!Zincln,!Protein!
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! .549! .153!  3.584! .001!
Protein! .002! .002! .159! .752! .456!
Zincln! .108! .096! .235! 1.116! .271!
a.!Dependent!Variable:!FemurBMD!
 
 
 
! 149 
m)!Model: Protein = HDL Cholesterol x Femur BMD x B12 x B6 x Energy x Magnesium x Zinc 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! Zincln,!
HDLlnnormalize
d,!FemurBMD,!
B12,!B6,!
Energy,!
Magnesiumlnb!
.! Enter!
a.!Dependent!Variable:!Protein!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .793a! .629! .550! 11.4036442000
00000!
a.!Predictors:!(Constant),!Zincln,!HDLlnnormalized,!FemurBMD,!B12,!
B6,!Energy,!Magnesiumln!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 7270.350! 7! 1038.621! 7.987! .000b!
Residual! 4291.422! 33! 130.043!   
Total! 11561.773! 40!    
a.!Dependent!Variable:!Protein!
b.!Predictors:!(Constant),!Zincln,!HDLlnnormalized,!FemurBMD,!B12,!B6,!Energy,!Magnesiumln!
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Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 5101.880! 53.104!  51.919! .064!
HDLlnnormalized! 6.691! 10.571! .079! .633! .531!
FemurBMD! 18.284! 12.394! .178! 1.475! .150!
B12! 2.206! 1.317! .208! 1.675! .103!
B6! 4.542! 4.734! .133! .959! .344!
Energy! .004! .005! .107! .715! .480!
Magnesiumln! 13.912! 8.768! .251! 1.587! .122!
Zincln! 10.410! 8.232! .222! 1.264! .215!
a.!Dependent!Variable:!Protein!
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n)! Model: Sleep = CRP 
 
Variables+Entered/Removeda!
Model!
Variables!
Entered!
Variables!
Removed! Method!
1! CReactiveProtei
nb!
.! Enter!
a.!Dependent!Variable:!Sleephours!
b.!All!requested!variables!entered.!
 
 
Model+Summary!
Model! R! R!Square!
Adjusted!R!
Square!
Std.!Error!of!the!
Estimate!
1! .267a! .071! .047! 1.179!
a.!Predictors:!(Constant),!CReactiveProtein!
 
 
ANOVAa!
Model! Sum!of!Squares! df! Mean!Square! F! Sig.!
1! Regression! 4.147! 1! 4.147! 2.982! .092b!
Residual! 54.243! 39! 1.391!   
Total! 58.390! 40!    
a.!Dependent!Variable:!Sleephours!
b.!Predictors:!(Constant),!CReactiveProtein!
 
 
Coefficientsa!
Model!
Unstandardized!Coefficients!
Standardized!
Coefficients!
t! Sig.!B! Std.!Error! Beta!
1! (Constant)! 6.578! .253!  25.963! .000!
CReactiveProtein! .785! .455! .267! 1.727! .092!
a.!Dependent!Variable:!Sleephours!
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